[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 181
1. Newsom-Davis T, Ahamed E, Bower M: Immunotherapy for HIV-associated non-Hodgkin's lymphoma. Expert Opin Biol Ther; 2009 Oct;9(10):1313-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy for HIV-associated non-Hodgkin's lymphoma.
  • The onset of the AIDS epidemic in 1981 was followed by descriptions of many opportunistic infections as well as several unusual cancers.
  • Non-Hodgkin's lymphoma (NHL) was classified as an AIDS-defining illness within 4 years, and is up to 200 times more common in HIV-positive patients.
  • Here, against a background of the history of immunotherapy, we review clinicopathological features of HIV-associated NHL and discuss current cancer immunotherapeutic treatments including immune reconstitution using highly active antiretroviral therapy (HAART), anti-CD20 monoclonal antibodies, radioimmunotherapy, stem cell transplantation, cytokine therapy and vaccination.
  • As the prognosis for HIV-associated NHL nears that of the general population, these approaches are of increasing importance and value.
  • [MeSH-major] Immunotherapy. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / therapy

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645631.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Cytokines
  • [Number-of-references] 100
  •  go-up   go-down


2. Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST: High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia; 2005 May;19(5):851-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.
  • We here report a high incidence of KSHV infection in solid HIV-associated immunoblastic/plasmablastic non-Hodgkin's lymphomas (NHLs), in patients lacking effusions and without evidence of (prior) MCD.
  • Within a cohort of 99 HIV-related NHLs, 10 cases were found to be KSHV positive on the basis of immunostaining for KSHV LNA-1 as well as KSHV-specific polymerase chain reaction.
  • Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-related solid immunoblastic/plasmablastic lymphomas.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology


3. Ayers LW, Silver S, McGrath MS, Orenstein JM: The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery. Infect Agent Cancer; 2007;2:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery.
  • The AIDS Cancer and Specimen Resource (ACSR) supports scientific discovery in the area of HIV/AIDS-associated malignancies.
  • The ACSR was established as a cooperative agreement between the NCI (Office of the Director, Division of Cancer Treatment and Diagnosis) and regional consortia, University of California, San Francisco (West Coast), George Washington University (East Coast) and Ohio State University (Mid-Region) to collect, preserve and disperse HIV-related tissues and biologic fluids and controls along with clinical data to qualified investigators.
  • The ACSR tissue bank has more than 100,000 human HIV positive specimens that represent different processing (43), specimen (15), and anatomical site (50) types.
  • Requests have been greatest for Kaposi's sarcoma (32%) and non-Hodgkin's lymphoma (26%).
  • ACSR also provides tissue microarrays of, e.g., Kaposi's sarcoma and non-Hodgkin's lymphoma, for biomarker assays and has developed collaborations with other groups that provide access to additional AIDS-related malignancy specimens.
  • The ACSR promotes the scientific exploration of the relationship between HIV/AIDS and malignancy by participation at national and international scientific meetings, contact with investigators who have productive research in this area and identifying, collecting, preserving, enhancing, and dispersing HIV/AIDS-related malignancy specimens to funded, approved researchers at no fee.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Res. 2003 Oct 15;60(1):108-18 [14522412.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2004;50 Online Pub:OL581-9 [15555424.001]
  • [Cites] Pediatr Infect Dis J. 2005 Mar;24(3):237-42 [15750460.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:12 [15871741.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1373-80 [15923317.001]
  • [Cites] Science. 2005 Jun 10;308(5728):1582-3 [15947174.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:25 [16086837.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):3-11 [16867895.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):696-701 [10655369.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Nat Med. 2001 Jan;7(1):73-9 [11135619.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):733-41 [12428794.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] BMC Med Inform Decis Mak. 2003 May 23;3:5 [12769826.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4620-9 [8977254.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Jan 20;13(2):135-49 [9007199.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • (PMID = 17335575.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066531
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1851770
  •  go-up   go-down


Advertisement
4. Keszler A, Piloni MJ, Paparella ML, Soler Mde D, Ron PC, Narbaitz M: Extranodal oral non-Hodgkin's lymphomas. A retrospective study of 40 cases in Argentina. Acta Odontol Latinoam; 2008;21(1):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal oral non-Hodgkin's lymphomas. A retrospective study of 40 cases in Argentina.
  • A retrospective study was conducted of extranodal oral Non-Hodgkin's Lymphomas diagnosed at the Surgical Pathology Laboratory of the School of Dentistry at Buenos Aires University, Argentina, between 1985 and 2004.
  • The most common histological type was Diffuse Large Cell Lymphoma.
  • 60% of the Plasmablastic Lymphomas in the series came from HIV+ patients.
  • [MeSH-major] Jaw Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Argentina. Child. Child, Preschool. Female. Humans. Lymphoma, AIDS-Related / pathology. Male. Middle Aged. Retrospective Studies. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841745.001).
  • [ISSN] 0326-4815
  • [Journal-full-title] Acta odontológica latinoamericana : AOL
  • [ISO-abbreviation] Acta Odontol Latinoam
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Argentina
  •  go-up   go-down


5. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M: Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis; 2009 Apr 15;48(8):1138-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
  • BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy.
  • Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretroviral therapy, and CD4+ cell count and HIV RNA load at initiation of combination antiretroviral therapy.
  • The greatest mortality hazard ratio was associated with non-Hodgkin's lymphoma (hazard ratio, 17.59; 95% confidence interval, 13.84-22.35) and progressive multifocal leukoencephalopathy (hazard ratio, 10.0; 95% confidence interval, 6.70-14.92).
  • Three groups of ADEs were identified on the basis of the ranked hazard ratios with bootstrapped confidence intervals: severe (non-Hodgkin's lymphoma and progressive multifocal leukoencephalopathy [hazard ratio, 7.26; 95% confidence interval, 5.55-9.48]), moderate (cryptococcosis, cerebral toxoplasmosis, AIDS dementia complex, disseminated Mycobacterium avium complex, and rare ADEs [hazard ratio, 2.35; 95% confidence interval, 1.76-3.13]), and mild (all other ADEs [hazard ratio, 1.47; 95% confidence interval, 1.08-2.00]).

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Mycobacterium avium Complex and Atypical Mycobacterial Infections in the Setting of HIV Infection .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Jul 13;360(9327):119-29 [12126821.001]
  • [Cites] JAMA. 2003 May 21;289(19):2554-9 [12759327.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] JAMA. 2004 Jul 14;292(2):180-9 [15249567.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] N Engl J Med. 1981 Dec 10;305(24):1425-31 [6272109.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):402-3 [2992336.001]
  • [Cites] JAMA. 1987 Sep 4;258(9):1143-5, 1149, 1153-4 [3041060.001]
  • [Cites] Ann Intern Med. 1991 Aug 1;115(3):184-9 [1676252.001]
  • [Cites] J Acquir Immune Defic Syndr. 1991;4(10):1059-71 [1890600.001]
  • [Cites] JAMA. 1992 Nov 18;268(19):2662-6 [1359163.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] BMJ. 1994 Apr 23;308(6936):1068-73 [7909698.001]
  • [Cites] Stat Med. 1994 Oct 15-30;13(19-20):2107-25 [7846414.001]
  • [Cites] AIDS. 1995 Jan;9(1):57-63 [7893442.001]
  • [Cites] Arch Intern Med. 1995 Jul 24;155(14):1537-42 [7605156.001]
  • [Cites] Int J Epidemiol. 1997 Apr;26(2):400-7 [9169177.001]
  • [Cites] AIDS. 1998 Jan 1;12(1):29-33 [9456252.001]
  • [Cites] Nat Med. 1998 Feb;4(2):208-14 [9461195.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):543-9 [9492772.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):121-30 [15561752.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):399-406 [15750393.001]
  • [Cites] Infection. 2005 Feb;33(1):43-5 [15750761.001]
  • [Cites] BMJ. 2005 Mar 12;330(7491):594-6 [15761002.001]
  • [Cites] J Infect Dis. 2005 Sep 15;192(6):992-1002 [16107951.001]
  • [Cites] Lancet. 2006 Mar 11;367(9513):817-24 [16530575.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2283-96 [17135583.001]
  • [Cites] AIDS. 2007 May 31;21(9):1185-97 [17502729.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1867-75 [17721094.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):111-8 [12048371.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):451-8 [11141245.001]
  • [Cites] J Infect Dis. 2002 Jan 15;185(2):178-87 [11807691.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):388-95 [11917244.001]
  • (PMID = 19275498.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA013566-08; United States / NIAAA NIH HHS / AA / U10 AA013566; United Kingdom / Medical Research Council / / G0700820; United States / NIAAA NIH HHS / AA / U10 AA013566-08
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS264818; NLM/ PMC3032444
  • [Investigator] Casabona J; Chêne G; Costagliola D; Dabis F; D'Arminio Monforte A; de Wolf F; Egger M; Fatkenheuer G; Gill J; Hogg R; Justice A; Kitahata M; Ledergerber B; Mocroft A; Phillips A; Reiss P; Saag M; Sabin C; Staszewski S; Weller I; May M; Harris R; Sterne J; Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Duvivier C; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong MA; Lang JM; Lascaux AS; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard JL; Pavie J; Pialoux G; Pilorgé F; Poizot-Martin I; Pradier C; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard JP; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Guiguet M; Kousignian I; Lanoy E; Lièvre L; Potard V; Selinger-Leneman H; Bouvet E; Crickx B; Ecobichon JL; Leport C; Picard-Dahan C; Yeni P; Tisne-Dessus D; Weiss L; Salmon D; Sicard D; Auperin I; Roudière L; Fior R; Delfraissy JF; Goujard C; Jung C; Lesprit P; Desplanque N; Meyohas MC; Picard O; Cadranel J; Mayaud C; Bricaire F; Herson S; Clauvel JP; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine JL; Trepo C; Ravaux I; Delmont JP; Moreau J; Gastaut JA; Retornaz F; Soubeyrand J; Allegre T; Blanc PA; Galinier A; Ruiz JM; Lepeu G; Granet-Brunello P; Esterni JP; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; May T; Rabaud C; Raffi F; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand MF; Yasdanpanah Y; Pradinaud R; Sobesky M; Contant M; Montroni M; Scalise G; Braschi MC; Riva A; Tirelli U; Martellotta F; Pastore G; Ladisa N; Suter F; Arici C; Chiodo F; Colangeli V; Fiorini C; Carosi G; Cristini G; Torti C; Minardi C; Bertelli D; Quirino T; Manconi PE; Piano P; Cosco L; Scerbo A; Vecchiet J; D'Alessandro M; Santoro D; Pusterla L; Carnevale G; Lorenzotti S; Viganò P; Mena M; Ghinelli F; Sighinolfi L; Leoncini F; Mazzotta F; Pozzi M; Lo Caputo S; Grisorio B; Ferrara S; Grima P; Grima PF; Pagano G; Cassola G; Alessandrini A; Piscopo R; Toti M; Trezzi M; Soscia F; Tacconi L; Orani A; Perini P; Scasso A; Vincenti A; Chiodera F; Castelli P; Scalzini A; Palvarini L; Moroni M; Lazzarin A; Rizzardini G; Caggese L; Cicconi P; Galli A; Merli S; Pastecchia C; Moioli MC; Esposito R; Mussini C; Abrescia N; Chirianni A; Izzo CM; Piazza M; De Marco M; Viglietti R; Manzillo E; Nappa S; Colomba A; Abbadessa V; Prestileo T; Mancuso S; Ferrari C; Pizzaferri P; Filice G; Minoli L; Bruno R; Novati S; Baldelli F; Camanni G; Petrelli E; Cioppi A; Alberici F; Ruggieri A; Menichetti F; Martinelli C; De Stefano C; La Gala A; Ballardini G; Rizzo E; Magnani G; Ursitti MA; Arlotti M; Ortolani P; Cauda R; Dianzani F; Ippolito G; Antinori A; Antonucci G; Ciardi M; Narciso P; Petrosillo N; Vullo V; De Luca A; Zaccarelli M; Acinapura R; De Longis P; Trotta MP; Noto P; Lichtner M; Capobianchi MR; Carletti F; Girardi E; Pezzotti P; Rezza G; Mura MS; Mannazzu M; Caramello P; Di Perri G; Orofino GC; Sciandra M; Grossi PA; Basilico C; Poggio A; Bottari G; Raise E; Ebo F; Pellizzer G; Buonfrate D; Resta F; Loso K; Cozzi Lepri A; Battegay M; Bernasconi E; Böni J; Bucher H; Bürgisser P; Cattacin S; Cavassini M; Dubs R; Elzi L; Erb P; Fischer M; Flepp M; Fontana A; Francioli P; Furrer H; Gorgievski M; Günthard H; Hirsch H; Hirschel B; Hösli I; Kahlert C; Kaiser L; Karrer U; Kind C; Klimkait T; Martinetti G; Martinez B; Müller N; Nadal D; Opravil M; Paccaud F; Pantaleo G; Rickenbach M; Rudin C; Schmid P; Schultze D; Schüpbach J; Speck R; Taffé P; Tarr P; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S; Gras LA; van Sighem AI; Smit C; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Branger J; Eeftinck Schattenkerk JK; Gisolf J; Godfried MH; Lange JM; Lettinga KD; van der Meer JT; Nellen FJ; van der Poll T; Ruys TA; Steingrover R; Vermeulen JN; Vrouenraets SM; van Vugt M; Wit FW; Kuijpers TW; Pajkrt D; Scherpbier HJ; van Eeden A; Brinkman K; van den Berk GE; Blok WL; Frissen PH; Roos JC; Schouten WE; Mulder JW; van Gorp EC; Wagenaar J; Veenstra J; Danner SA; Van Agtmael MA; Claessen FA; Perenboom RM; Rijkeboer A; van Vonderen MG; Richter C; van der Berg J; Vriesendorp R; Jeurissen FJ; Kauffmann RH; Pogány K; Bravenboer B; ten Napel CH; Kootstra GJ; Sprenger HG; van Assen S; van Leeuwen JT; Doedens R; Scholvinck EH; ten Kate RW; Soetekouw R; van Houte D; Polée MB; Kroon FP; van den Broek PJ; van Dissel JT; Schippers EF; Schreij G; van der Geest S; Lowe S; Verbon A; Koopmans PP; Van Crevel R; de Groot R; Keuter M; Post F; van der Ven AJ; Warris A; van der Ende ME; Gyssens IC; van der Feltz M; Nouwen JL; Rijnders BJ; de Vries TE; Driessen G; van der Flier M; Hartwig NG; Juttman JR; van Kasteren ME; Van de Heul C; Hoepelman IM; Schneider MM; Bonten MJ; Borleffs JC; Ellerbroek PM; Jaspers CA; Mudrikove T; Schurink CA; Gisolf EH; Geelen SP; Wolfs TF; Faber T; Tanis AA; Groeneveld PH; den Hollander JG; Duits AJ; Winkel K; Back NK; Bakker ME; Berkhout B; Jurriaans S; Zaaijer HL; Cuijpers T; Rietra PJ; Roozendaal KJ; Pauw W; van Zanten AP; Smits PH; von Blomberg BM; Savelkoul P; Pettersson A; Swanink CM; Franck PF; Lampe AS; Jansen CL; Hendriks R; Benne CA; Veenendaal D; Storm H; Weel J; van Zeijl JH; Kroes AC; Claas HC; Bruggeman CA; Goossens VJ; Galama JM; Melchers WJ; Poort YA; Doornum GJ; Niesters MG; Osterhaus AD; Schutten M; Buiting AG; Swaans CA; Boucher CA; Schuurman R; Boel E; Jansz AF; Veldkamp A; Beijnen JH; Huitema AD; Burger DM; Hugen PW; van Kan HJ; Losso M; Duran A; Vetter N; Karpov I; Vassilenko A; Mitsura VM; Suetnov O; Clumeck N; De Wit S; Poll B; Colebunders R; Kostov K; Begovac J; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Lundgren J; Benfield T; Kirk O; Gerstoft J; Katzenstein T; Hansen AB; Skinhøj P; Pedersen C; Oestergaard L; Zilmer K; Ristola M; Girard PM; Vanhems P; Rockstroh J; Schmidt R; van Lunzen J; Degen O; Stellbrink HJ; Bogner J; Kosmidis J; Gargalianos P; Xylomenos G; Perdios J; Panos G; Filandras A; Karabatsaki E; Sambattakou H; Banhegyi D; Mulcahy F; Yust I; Turner D; Burke M; Pollack S; Hassoun G; Maayan S; Chiesi A; Mazeu I; Pristera R; Gabbuti A; Montesarchio E; Gargiulo M; Iacomi F; Vlassi C; Finazzi R; Galli M; Ridolfo A; Rozentale B; Aldins P; Chaplinskas S; Hemmer R; Staub T; Bruun J; Maeland A; Ormaasen V; Knysz B; Gasiorowski J; Horban A; Prokopowicz D; Wiercinska-Drapalo A; Boron-Kaczmarska A; Pynka M; Beniowski M; Mularska E; Trocha H; Antunes F; Valadas E; Mansinho K; Maltez F; Duiculescu D; Rakhmanova A; Vinogradova E; Buzunova S; Jevtovic D; Mokrás M; Staneková D; González-Lahoz J; Soriano V; Martin-Carbonero L; Labarga P; Clotet B; Jou A; Conejero J; Tural C; Gatell JM; Miró JM; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Karlsson A; Persson PO; Flamholc L; Boffi E; Kravchenko E; Chentsova N; Barton S; Johnson AM; Mercey D; Johnson MA; Murphy M; Weber J; Scullard G; Fisher M; Brettle R; Gatell J; Gazzard B; Friis-Møller N; Bannister W; Ellefson M; Borch A; Podlekareva D; Holkmann Olsen C; Kjaer J; Peters L; Reekie J; Raffanti S; Dieterch D; Becker S; Scarsella A; Fusco G; Most B; Balu R; Rana R; Beckerman R; Ising T; Fusco J; Irek R; Johnson B; Hirani A; DeJesus E; Pierone G; Lackey P; Irek C; Johnson A; Burdick J; Leon S; Arch J; Helm EB; Carlebach A; Müller A; Haberl A; Nisius G; Lennemann T; Stephan C; Bickel M; Mösch M; Gute P; Locher L; Lutz T; Klauke S; Knecht G; Khaykin P; Doerr HW; Stürmer M; Babacan E; von Hentig N; Beylot J; Dupon M; Longy-Boursier M; Pellegrin JL; Ragnaud JM; Salamon R; Thiébaut R; Lewden C; Lawson-Ayayi S; Dupon M; Mercié P; Moreau JF; Morlat P; Bernard N; Lacoste D; Malvy D; Neau D; Blaizeau MJ; Decoin M; Delveaux S; Hannapier C; Labarrère S; Lavignolle-Aurillac V; Uwamaliya-Nziyumvira B; Palmer G; Touchard D; Balestre E; Alioum A; Jacqmin-Gadda H; Bonarek M; Bonnet F; Coadou B; Gellie P; Nouts C; Bocquentin F; Dutronc H; Lafarie S; Aslan A; Pistonne T; Thibaut P; Vatan R; Chambon D; De La Taille C; Cazorla C; Ocho A; Viallard JF; Caubet O; Cipriano C; Lazaro E; Couzigou P; Castera L; Fleury H; Lafon ME; Masquelier B; Pellegrin I; Breilh D; Blanco P; Loste P; Caunègre L; Bonnal F; Farbos S; Ferrand M; Ceccaldi J; Tchamgoué S; De Witte S; Buy E; Alexander C; Barrios R; Braitstein P; Brumme Z; Chan K; Cote H; Gataric N; Geller J; Guillemi S; Harrigan PR; Harris M; Joy R; Levy A; Montaner J; Montessori V; Palepu A; Phillips E; Phillips P; Press N; Tyndall M; Wood E; Yip B; Bhagani S; Breen R; Byrne P; Carroll A; Cuthbertson Z; Dunleavy A; Geretti AM; Heelan B; Johnson M; Kinloch-de Loes S; Lipman M; Madge S; Marshall N; Nair D; Nebbia G; Prinz B; Shah S; Swader L; Tyrer M; Youle M; Chaloner C; Grabowska H; Holloway J; Puradiredja J; Ransom D; Tsintas R; Bansi L; Fox Z; Harris E; Hill T; Lampe F; Lodwick R; Smith C; Amoah E; Booth C; Clewley G; Garcia Diaz A; Gregory B; Janossy G; Labbett W; Thomas M; Read R; Krentz H; Beckthold B; Schmeisser N; Alquézar A; Esteve A; Podzamczer D; Murillas J; Romero A; Agustí C; Agüero F; Ferrer E; Riera M; Segura F; Navarro G; Force L; Vilaró J; Masabeu A; García I; Guadarrama M; Montoliu A; Ortega N; Lazzari E; Puchol E; Sanchez M; Blanco JL; Garcia-Alcaide F; Martinez E; Mallolas J; López-Dieguez M; García-Goez JF; Sirera G; Romeu J; Negredo E; Miranda C; Capitan MC; Olmo M; Barragan P; Saumoy M; Bolao F; Cabellos C; Peña C; Sala M; Cervantes M; Jose Amengual M; Navarro M; Penelo E; Barrufet P; Raper JL; Mugavero MJ; Willig JH; Schumacher J; Chang PW; Westfall AO; Cloud G; Lin HY; Acosta EP; Colette-Kempf M; Allison JJ; Pisu M
  •  go-up   go-down


6. De Paoli P: Novel virally targeted therapies of EBV-associated tumors. Curr Cancer Drug Targets; 2008 Nov;8(7):591-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel virally targeted therapies of EBV-associated tumors.
  • EBV is associated to the development of several malignancies of lymphoid and epithelial origin, including Burkitt's Lymphoma, post-transplant lymphoproliferative disorders, Hodgkin's disease, AIDS-associated lymphomas, NK/T cell lymphoma and Nasopharyngeal carcinoma.
  • EBV genes play an essential role in the development of the malignant phenotype and therefore molecules interfering with the function of these genes may represent an essential tool to treat EBV-associated malignancies.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991568.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 122
  •  go-up   go-down


7. Heise W: GI-lymphomas in immunosuppressed patients (organ transplantation; HIV). Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):57-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GI-lymphomas in immunosuppressed patients (organ transplantation; HIV).
  • Gastrointestinal lymphoma plays a major role complicating different diseases presenting with immunosuppression, both primary and acquired immunodeficiency (incl.
  • HIV, transplantation, immunosuppression following chemotherapy, or inflammatory bowel disease).
  • Lymphoma in diseases with immunosuppression are clinically and pathologically heterogeneous, but share some features such as frequent involvement of extranodal sites, diffuse aggressive histology, B-cell lineage derivation, viral association with EBV and clinically aggressive courses.
  • While gastrointestinal lymphoma in congenital immunodeficiency disorders seems to be a rare event inspite of higher prevalences, in post-transplant lymphoproliferative disorders (PTLD) the gastrointestinal tract is one of the most important organs of lymphoma.
  • In HIV-associated non-Hodgkin's lymphoma, gastrointestinal lesions as the most frequent extranodal localisation occur in 30-50% of lymphoma patients, are late events of HIV infection with severe immunosuppression and are mainly diagnosed with advanced disease stages Ann Arbour III or IV.
  • With the introduction of highly active antiretroviral therapy (HAART) in the therapeutic concept in AIDS, a decrease of AIDS-related GI lymphoma was noted with improved survival rates and prognosis of lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / immunology. HIV Infections / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lymphoma / immunology. Lymphoma, AIDS-Related / immunology. Organ Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206109.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 84
  •  go-up   go-down


8. Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E: Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol; 2005 Jul 1;23(19):4372-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
  • PURPOSE: Primary effusion lymphoma (PEL) is a rare high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) infection, and is mostly observed in the course of HIV infection.
  • To date, no prognostic factor has been identified in this subset of lymphoma.
  • PATIENTS AND METHODS: We describe here a large series of HIV-infected patients with PEL, including 28 cases diagnosed in six centers during an 11-year time period.
  • Fourteen patients (50%) achieved complete remission, with a 1-year disease-free survival rate at 78.6%.
  • CONCLUSION: Based on a retrospective series of 28 patients, two prognostic factors were identified as being independently associated with impaired clinical outcome in HIV-related PEL--(1) a poor performance status and (2) the absence of HAART before PEL diagnosis.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Herpesvirus 8, Human. Lymphoma, AIDS-Related / mortality


9. Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV: Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? Eur J Haematol; 2007 Feb;78(2):152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we highlight two cases in which the cytogenetic studies challenge the common practice of using hematologic and morphologic changes as key factors in malignant disease management.
  • The first case is that of a lymph node sample from a 40-yr-old non-Hodgkin's lymphoma (NHL) patient sent for determination of disease progress.
  • Cytogenetic studies of lymph node showed multiple clonal abnormalities, most notably a der(18) from a t(14;18) which is associated with high-grade NHL.
  • After two cycles of chemotherapy with fludarabine, the patient did not show any clinical response, suggesting possible progression to high-grade lymphoma.
  • The second case is of a patient with a history of human immunodeficiency virus and blastic natural killer leukemia/lymphoma.
  • Hematologic studies of ascitic fluid classified the patient as having pleural effusion lymphoma whereas bone marrow analysis showed no malignancy.
  • Bone marrow cytogenetic studies showed multiple clonal abnormalities including a t(8;14), which is commonly associated with Burkitt's lymphoma (BL).
  • To our knowledge, this is the first case wherein a morphologically normal bone marrow showed presence of clonal abnormalities consistent with BL or Pleural effusion lymphoma.
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Follicular / genetics. Lymphoma, Non-Hodgkin / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 12 / ultrastructure. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 18 / ultrastructure. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 8 / ultrastructure. Chromosomes, Human, X. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm. Female. Genes, myc. Humans. Karyotyping. Lymph Nodes / pathology. Male. Mutagenesis, Insertional. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / pathology. Prednisone / administration & dosage. Rituximab. Trisomy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313561.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


10. Jacomet C, Lesens O, Villemagne B, Darcha C, Tournilhac O, Henquell C, Cormerais L, Gourdon F, Peigue-Lafeuille H, Travade P, Beytout J, Laurichesse H: [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003]. Med Mal Infect; 2006 Mar;36(3):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
  • OBJECTIVES: The authors had for aim to identify cases of non Hodgkin's (NHL) and Hodgkin's (HL) lymphomas in HIV1-infected patients to assess 1) their incidence, before and after 1996, 2) the clinical features and outcome under treatment together with the survival rate of the patients, 3) the immune reconstitution of lymphoma-free patients under HAART.
  • PATIENTS AND METHODS: A retrospective study was made of HIV1-infected patients managed at the Clermont-Ferrand University Hospital from 1991 to 2003 for the diagnosis and treatment of HIV1-related lymphomas.
  • A high proportion of aggressive and disseminated disease was observed among NHL cases.
  • The mean survival was 109+/-54 months and was correlated with CD4 cell count at lymphoma diagnosis (univariate analysis).
  • CONCLUSIONS: The incidence of lymphomas in HIV-infected patients has not decreased since the introduction of HAART.
  • Immune restoration in lymphoma-free patients under HAART is poor.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. HIV-1. Hodgkin Disease / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Cohort Studies. Female. France / epidemiology. Hospitals, University / statistics & numerical data. Humans. Incidence. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome


11. Diamond C, Taylor TH, Im T, Miradi M, Anton-Culver H: Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol; 2006 Sep;24(3):139-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy.
  • Using the population-based cancer registry, we identified 233 patients with AIDS-related systemic NHL diagnosed in San Diego or Orange County in 1994-1999, of whom 137 were diagnosed 1996-1999.
  • HAART, chemotherapy, high performance status, and NHL stage < IV were associated with improved survival.
  • Concomitant HAART, completion of > or = 6 chemotherapy cycles, and NHL stage < IV were associated with complete response to chemotherapy.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 John Wiley & Sons, Ltd.
  • (PMID = 16604565.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K07CA096480
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


12. Barbaro G, Barbarini G: HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Rep; 2007 May;17(5):1121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
  • The majority of cancers affecting HIV-infected subjects are those established as acquired immunodeficiency syndrome (AIDS)-defining: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), and invasive cervical cancer (ICC).
  • However, other types of cancer, such as Hodgkin's disease (HD), anal cancer, lung cancer and testicular germ cell tumors appear to be more common among HIV-infected subjects compared to the general population.
  • While not classified as AIDS-defining, these malignancies have been referred to as AIDS-associated malignancies.
  • The mechanisms by which depressed immunity could increase the risk for cancer are unclear, except for in KS and most subtypes of NHL, where it is strictly associated with a low CD4 count.
  • Although it remains unclear whether HIV-1 acts directly as an oncogenic agent, it may contribute to the development of malignancies through several mechanisms (e.g., infection by oncogenic viruses, impaired immune surveillance, imbalance between cellular proliferation and differentiation).
  • Studies of the effect of highly active antiretroviral therapy (HAART) on the incidence and progression of HIV/AIDS-associated cancers provided contrasting data.
  • While a significant decrease in the incidence of KS has been observed, HAART has not had a significant impact on NHL incidence, particularly systemic NHL, or on ICC, HD, anal cancers and other non-AIDS-defining cancers.
  • Regardless of whether these cancers are directly related to HIV-induced immunodeficiency, treating cancer in HIV-infected patients remains a challenge because of drug interactions, compounded side effects, and the potential effect of chemotherapy on CD4 count and HIV-1 viral load.
  • A better knowledge of viral mechanisms of immune evasion and manipulation will provide the basis for a better management and treatment of the malignancies associated with chronic viral infections.
  • [MeSH-major] HIV Infections / complications. HIV Infections / drug therapy. HIV-1. Neoplasms / virology


13. Kristinsson SY, Goldin LR, Björkholm M, Koshiol J, Turesson I, Landgren O: Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica; 2009 Nov;94(11):1581-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.
  • There are data to support a role for genetic and immune-related factors in the pathogenesis of lymphomas and plasma cell diseases.
  • In this paper, we review our published large population-based studies and other relevant studies in Hodgkin's and non-Hodgkin's lymphomas, multiple myeloma, and the precursor condition monoclonal gammopathy of undetermined significance.
  • We discuss the overlap in risk factors between related malignancies and explore the underlying mechanisms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Rheumatol. 2007 Oct;3(10):561-9 [17906611.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3326-33 [17687107.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):717-23 [18021086.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):762-71 [18021089.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1468-73 [18053453.001]
  • [Cites] Arthritis Rheum. 2008 Mar;58(3):657-66 [18311836.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3388-94 [18239085.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 17;85(4):307-11 [8426374.001]
  • [Cites] Cancer Causes Control. 1993 Jul;4(4):361-8 [8347786.001]
  • [Cites] Leukemia. 1993 Sep;7(9):1363-9 [8371587.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2378-85 [8162584.001]
  • [Cites] Scand J Immunol. 1994 Aug;40(2):195-200 [8047841.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1943-9 [8656264.001]
  • [Cites] J Rheumatol. 1996 Jun;23(6):1095-7 [8782146.001]
  • [Cites] Eur J Cancer. 1996 Sep;32A(10):1753-7 [8983286.001]
  • [Cites] Haematologica. 2005 Jan;90(1):66-71 [15642671.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Blood. 2005 Jul 15;106(2):668-72 [15811955.001]
  • [Cites] J Med Genet. 2005 Jul;42(7):595-601 [15994882.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Am J Epidemiol. 2005 Dec 15;162(12):1153-61 [16251389.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Blood. 2006 Feb 1;107(3):904-6 [16210333.001]
  • [Cites] N Engl J Med. 2008 Jul 10;359(2):152-7 [18614782.001]
  • [Cites] Lupus. 2008 Jul;17(7):613-4 [18625632.001]
  • [Cites] Arch Intern Med. 2008 Sep 22;168(17):1903-9 [18809818.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1204-10 [18758461.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3052-6 [18703425.001]
  • [Cites] N Engl J Med. 2008 Oct 16;359(16):1734-5; author reply 1735 [18923179.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Am J Med. 1985 Jan 21;78(1A):29-32 [3970037.001]
  • [Cites] Br J Haematol. 1985 Jul;60(3):551-4 [3925983.001]
  • [Cites] J Natl Cancer Inst. 1986 Aug;77(2):371-8 [3461199.001]
  • [Cites] Br J Cancer. 1987 Jan;55(1):85-90 [3814482.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2978-81 [3567914.001]
  • [Cites] Leuk Res. 1988;12(1):81-8 [3357350.001]
  • [Cites] Am J Pathol. 1988 Oct;133(1):173-92 [2845789.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):353-7 [3222144.001]
  • [Cites] Am J Epidemiol. 1991 Jul 1;134(1):22-8 [1853857.001]
  • [Cites] Cancer Causes Control. 1992 Jan;3(1):63-7 [1536915.001]
  • [Cites] Haematologica. 2009 May;94(5):647-53 [19286886.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):398-405 [19365835.001]
  • [Cites] Br J Haematol. 2009 Jun;146(1):91-4 [19438470.001]
  • [Cites] Blood. 2009 Jul 23;114(4):785-90 [19179466.001]
  • [Cites] Blood. 2009 Jul 23;114(4):791-5 [19182202.001]
  • [Cites] Haematologica. 2009 Aug;94(8):1179-81 [19546435.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2147-50 [19582882.001]
  • [Cites] Hum Genet. 2000 May;106(5):553-6 [10914686.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):497-502 [11054684.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):793-5 [11526388.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1979-81 [11535538.001]
  • [Cites] APMIS. 2001 Nov;109(11):797-800 [11900061.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3909-15 [12010788.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):963-70 [12687538.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):347-54 [15251127.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Blood. 1966 Apr;27(4):435-48 [5327005.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Scand J Haematol. 1977 Oct;19(4):396-404 [562530.001]
  • [Cites] Cancer. 1977 Nov;40(5):2094-101 [336182.001]
  • [Cites] Acta Med Scand. 1982 May;211(3):237-9 [6805257.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Cancer Causes Control. 1992 Sep;3(5):449-56 [1525326.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):488-94 [16357024.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3095-8 [16395700.001]
  • [Cites] Blood. 2006 Jul 1;108(1):292-6 [16527887.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Semin Immunol. 2006 Oct;18(5):305-17 [16916610.001]
  • [Cites] Am J Hum Genet. 2006 Oct;79(4):695-701 [16960805.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1697-700 [17145609.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3774-81 [17133544.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2198-201 [17082317.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:40-61 [17405120.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Cell. 2007 Jul 13;130(1):25-35 [17632054.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1260-7 [17426058.001]
  • [Cites] Expert Opin Pharmacother. 2007 Sep;8(13):2089-107 [17714062.001]
  • (PMID = 19586941.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2770969
  •  go-up   go-down


14. Vanisri HR, Nandini NM, Sunila R: Fine-needle aspiration cytology findings in human immunodeficiency virus lymphadenopathy. Indian J Pathol Microbiol; 2008 Oct-Dec;51(4):481-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-six human immunodeficiency virus (HIV)-positive patients with lymphadenopathy were subjected to fine-needle aspiration cytology (FNAC) over a period of 2 years.
  • The maximum number of cases had tuberculosis (58.3%) followed by reactive lymphadenitis (36.1%), non-Hodgkin's lymphoma (2.7%) and acute suppurative lymphadenitis (2.7%).
  • FNAC is an important diagnostic tool in the evaluation of lymphadenopathy in HIV-positive patients.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / pathology. Biopsy, Fine-Needle. HIV Infections / complications. Lymphatic Diseases / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Lymphadenitis / complications. Lymphadenitis / epidemiology. Lymphadenitis / pathology. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / pathology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Tuberculosis, Lymph Node / complications. Tuberculosis, Lymph Node / epidemiology. Tuberculosis, Lymph Node / pathology. Young Adult


15. Baehring JM, Hochberg FH: Primary lymphoma of the nervous system. Cancer J; 2006 Jan-Feb;12(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the nervous system.
  • This review article provides guidelines for the diagnosis, staging, and management of primary nervous system lymphoma based on the results of clinical trials conducted during the last decade.
  • Recent progress in our understanding of the pathogenesis of primary nervous system lymphoma is summarized, and implications of these findings for the development of diagnostic tools and new therapeutic strategies are outlined.
  • We performed a search of the PubMed database (National Center for Biotechnology Information) for articles on primary nervous system lymphoma published between 1970 and May 2005.
  • Primary nervous system lymphoma affects the brain, eye, and meninges as well as cranial, spinal, and peripheral nerves.
  • Although important lessons have been learned from the pathogenesis of extraneural non-Hodgkin's lymphoma, the unique organotropism of primary nervous system lymphoma remains poorly understood.
  • Long-term survival and, in selected cases, even a cure are possible in primary nervous system lymphoma.
  • A deeper understanding of the pathogenesis of primary nervous system lymphoma may reveal new therapeutic targets.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Nervous System Neoplasms / diagnosis. Nervous System Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Eye Neoplasms / therapy. Humans. Lymphoma, AIDS-Related / therapy. Magnetic Resonance Imaging. Methotrexate / therapeutic use. Organ Transplantation. Radiotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613654.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 108
  •  go-up   go-down


16. Sabaawy HE, Sandoval C, Guo Q, Yin C, Kulangara A, Lee J, Wormser G, Jayabose S, Pine SR: Lymphoproliferative clonal origin of AIDS-related non-Hodgkin's lymphoma. Leuk Lymphoma; 2007 Apr;48(4):812-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoproliferative clonal origin of AIDS-related non-Hodgkin's lymphoma.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / genetics. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics. Lymphoproliferative Disorders / genetics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454643.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


17. Bosch Príncep R, Lejeune M, Salvadó Usach MT, Jaén Martínez J, Pons Ferré LE, Alvaro Naranjo T: Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Ann Hematol; 2005 Oct;84(10):661-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma.
  • This study aimed to assess the differences in the cellular composition of the inflammatory reactive background around tumoral cells of classical Hodgkin's lymphomas (cHL) inside and outside the HIV settings.
  • Sections from paraffin-embedded tumor samples from nine HIV-infected cHL patients were immunostained, using standard immunohistochemical protocols and were compared to a control group of 90 HIV-noninfected cHL patients.
  • Our clinical and histological data indicate that HIV-infected cHL patients present a higher frequency of mixed cellularity (MC) histological subtypes, more advanced disease stages, a poor response to treatment, and a poor overall survival compared to control patients.
  • The inflammatory infiltrate of HIV-infected patients had a significant reduction of CD4+ T lymphocytes (CD4/CD8 ratio 1:23), a decrease in infiltrating GrB+ cells (activated cytotoxic cells) and an increase in infiltrating TIA+ T cells (mainly nonactivated cytotoxic cells) in these patients (GrB/TIA-1 ratio 1:12).
  • In conclusion, this study highlights an important intratumoral loss of CD4+ T cells (striking inversion in the CD4/CD8 ratio) and a decrease in intratumoral activated cytotoxic T lymphocytes in HIV-associated cHL patients.
  • Further studies are required to confirm these results and to determine the role of these findings on the antitumoral immune response observed in HIV-associated cHL.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CD8-Positive T-Lymphocytes / metabolism. HIV. HIV Infections / metabolism. Hodgkin Disease / metabolism. Serine Endopeptidases / metabolism


18. Nyagol J, De Falco G, Lazzi S, Luzzi A, Cerino G, Shaheen S, Palummo N, Bellan C, Spina D, Leoncini L: HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. J Hematop; 2008 Jul;1(1):3-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.
  • In some subtypes of non-Hodgkin's lymphomas, higher local vascular endothelial growth factor (VEGF) expression correlates with increased microvessel density.
  • Several studies have indicated that VEGF receptors are also targeted by Tat protein from the HIV-1-infected cells.
  • We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL).
  • Reduced VEGF protein expression in primary HIV-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines.
  • Microvascular density assessed by CD34 expression was, however, higher in HIV-1 positive than in HIV-1 negative tumors.
  • Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1996 Dec;2(12):1371-5 [8946838.001]
  • [Cites] Oncogene. 2000 Jan 20;19(3):373-9 [10656684.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):289-97 [8570206.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2014-21 [17917969.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]
  • [Cites] Exp Cell Res. 2007 May 1;313(8):1561-74 [17382929.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1362-9 [17392174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52 [17360578.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):693-9 [17320821.001]
  • [Cites] Nat Struct Mol Biol. 2007 Mar;14(3):249-50 [17293873.001]
  • [Cites] J Cell Biochem. 2007 Feb 15;100(3):727-37 [17115409.001]
  • [Cites] Curr Med Chem. 2006;13(16):1845-57 [16842197.001]
  • [Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):241-3 [15704651.001]
  • [Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]
  • [Cites] Circulation. 1997 Dec 2;96(11):4083-94 [9403634.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31119-24 [9813014.001]
  • [Cites] Science. 1998 Dec 4;282(5395):1837-9 [9874635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]
  • [Cites] J Clin Pathol. 1997 Jun;50(6):481-4 [9378813.001]
  • [Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] Nature. 1994 Oct 20;371(6499):674-80 [7935812.001]
  • [Cites] Arch Orthop Trauma Surg. 2003 Nov;123(9):475-80 [12750926.001]
  • [Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]
  • [Cites] Cell Prolif. 2003 Jun;36(3):131-49 [12814430.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]
  • [Cites] J Rheumatol. 2003 Feb;30(2):260-8 [12563678.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):723-31 [12196924.001]
  • [Cites] Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44 [11965229.001]
  • [Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):838-45 [11764072.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):569-78 [11171054.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):462-8 [11212232.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):445-9 [10975552.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71 [10873597.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1065-74 [8644848.001]
  • (PMID = 19669199.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2712328
  •  go-up   go-down


19. Deeken JF, Pantanowitz L, Dezube BJ: Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol; 2009 Sep;21(5):445-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.
  • PURPOSE OF REVIEW: Highly active antiretroviral therapy has led to a dramatic improvement in the prognosis of patients diagnosed with HIV and AIDS.
  • This includes a significant decline in the rates of AIDS-related cancers, including Kaposi's sarcoma and non-Hodgkin's lymphoma.
  • Unfortunately, rates of non-AIDS-defining cancers are on the rise, and now exceed the rates of AIDS-related cancers in patients with HIV.
  • Treating non-AIDS-defining cancers in patients who are on highly active antiretroviral therapy is an open and complicated clinical question.
  • Unfortunately little is known about possible drug-drug interactions because HIV patients are typically excluded from clinical trials.
  • We conclude with considerations on how to use these new agents to treat non-AIDS-defining cancers, and discuss a future research agenda to better understand and predict potential highly active antiretroviral therapy-targeted therapy interactions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Neoplasms / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Pharmacol. 2008 Jan;64(1):31-41 [18000659.001]
  • [Cites] J Clin Pharmacol. 2008 Feb;48(2):209-14 [18077730.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:27-37 [18333863.001]
  • [Cites] Br J Cancer. 2008 Jun 3;98(11):1797-802 [18458675.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Drug Metab Dispos. 2008 Sep;36(9):1828-39 [18556438.001]
  • [Cites] J Clin Pharmacol. 2008 Sep;48(9):1032-40 [18728241.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408 [18806898.001]
  • [Cites] Top HIV Med. 2008 Oct-Nov;16(4):117-21 [18838745.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2 [18926092.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88 [18985183.001]
  • [Cites] Clin Ther. 2008 Nov;30(11):1956-75 [19108785.001]
  • [Cites] Clin Genitourin Cancer. 2009 Jan;7(1):24-7 [19213664.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(4):579-87 [19101137.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Dec;30(10):761-82 [19271026.001]
  • [Cites] Br J Clin Pharmacol. 2009 Apr;67(4):421-6 [19371315.001]
  • [Cites] Clin Pharmacokinet. 2009;48(3):199-209 [19385713.001]
  • [Cites] Drug Metab Dispos. 2009 Jun;37(6):1242-50 [19282395.001]
  • [Cites] Drug Metab Dispos. 1999 Dec;27(12):1488-95 [10570031.001]
  • [Cites] Drug Metab Dispos. 2001 Feb;29(2):100-2 [11159797.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46 [19455266.001]
  • [Cites] Clin Pharmacol Ther. 1990 May;47(5):647-54 [2111751.001]
  • [Cites] Drug Metab Dispos. 1990 May-Jun;18(3):369-72 [1974201.001]
  • [Cites] AIDS. 1992 Dec;6(12):1471-5 [1283519.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Apr;277(1):423-31 [8613951.001]
  • [Cites] Drug Metab Dispos. 1997 Feb;25(2):256-66 [9029057.001]
  • [Cites] J Clin Pharmacol. 1998 Feb;38(2):106-11 [9549640.001]
  • [Cites] Drug Metab Dispos. 1998 Jun;26(6):552-61 [9616191.001]
  • [Cites] J Pharm Sci. 1998 Jul;87(7):803-7 [9649346.001]
  • [Cites] Drug Metab Dispos. 1998 Jul;26(7):609-16 [9660842.001]
  • [Cites] Drug Metab Dispos. 1999 Jan;27(1):86-91 [9884314.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):902-8 [10421617.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Clin Pharmacokinet. 2005;44(2):111-45 [15656694.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Clin Colorectal Cancer. 2005 Sep;5(3):188-96 [16197622.001]
  • [Cites] Drug Metab Dispos. 2005 Nov;33(11):1723-8 [16103134.001]
  • [Cites] Drug Metab Dispos. 2005 Nov;33(11):1729-39 [16118329.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):144-51 [16397036.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85 [16433896.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):685-92 [16133532.001]
  • [Cites] Drug Metab Dispos. 2006 Mar;34(3):420-6 [16381666.001]
  • [Cites] Drug Metab Dispos. 2006 Apr;34(4):702-8 [16443666.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] JAMA. 2006 Aug 16;296(7):827-43 [16905788.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8 [16940065.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:27-30 [17159773.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):55-63 [17095207.001]
  • [Cites] Drug Metab Dispos. 2007 Apr;35(4):602-6 [17267620.001]
  • [Cites] Clin Pharmacol Ther. 2002 Jul;72(1):1-9 [12151999.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2255-7 [12369853.001]
  • [Cites] Chem Biol Interact. 2002 Nov 10;142(1-2):135-54 [12399160.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):471-8 [12748309.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4009-16 [12873999.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1855-9 [14612892.001]
  • [Cites] Int J Clin Pharmacol Ther. 2003 Dec;41(12):618-9 [14692719.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40 [15247556.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):290-4 [15138710.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3207-13 [17185463.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2684-91 [17473200.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Pharmacotherapy. 2007 Jun;27(6):888-909 [17542771.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3731-7 [17575239.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4849-57 [17699864.001]
  • [Cites] Drug Metab Dispos. 2007 Sep;35(9):1554-63 [17540708.001]
  • [Cites] Drug Metab Dispos. 2007 Sep;35(9):1657-63 [17591678.001]
  • [Cites] J Clin Pharmacol. 2007 Nov;47(11):1430-9 [17913896.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3540-6 [17715389.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7394-400 [18094422.001]
  • (PMID = 19606034.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 118
  • [Other-IDs] NLM/ NIHMS382143; NLM/ PMC3377583
  •  go-up   go-down


20. Langner-Wegscheider BJ, ten Dam-van Loon N, Mura M, Faridpooya K, de Smet MD: Intravitreal ganciclovir in the management of non-AIDS-related human cytomegalovirus retinitis. Can J Ophthalmol; 2010 Apr;45(2):157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravitreal ganciclovir in the management of non-AIDS-related human cytomegalovirus retinitis.
  • OBJECTIVE: To report and evaluate intravitreal ganciclovir injections in non-AIDS patients with human cytomegalovirus (HCMV) retinitis.
  • PARTICIPANTS: Two SLE patients and one patient post chemotherapy for a non Hodgkin's lymphoma presented with myelosuppression and persistent cytomegalovirus retinitis despite systemic ganciclovir therapy.
  • One patient had persistent smouldering disease and reached quiescence using an intravitreal ganciclovir implant.


21. Krentz HB, Kliewer G, Gill MJ: Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med; 2005 Mar;6(2):99-106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.
  • OBJECTIVES: To examine changes over a 2-year period in both the mortality rate and the causes of death in a geographically defined HIV-infected population.
  • METHODS: A database search of primary care information for the dates and causes of death for all patients documented with HIV infection and living in Southern Alberta between 1984 and 2003 was undertaken.
  • AIDS deaths were reconciled with Public Health Reports.
  • RESULTS: Between 1984 and 2003, there were 560 deaths in the 1987 individuals living with HIV infection in Southern Alberta.
  • In the pre-HAART era, 90% of all deaths were AIDS related whereas only 67% were AIDS related in the current HAART era.
  • The leading causes of AIDS deaths were AIDS multiple causes (31%), Mycobacterium avium complex (18%), Pneumocystis pneumonia (10%) and non-Hodgkin's lymphoma (7%).
  • The proportion of non-AIDS related deaths increased from 7% pre-HAART to 32% in the current HAART era.
  • Accidental deaths, including drug overdose (29%), suicide (7%) and violence (3%), hepatic disease (19%), non-AIDS related malignancies (19%), and cardiovascular disease (16%) accounted for the majority of non-AIDS related deaths.
  • A total of 14% of patients dying from AIDS were ARV-naive in contrast to 35% dying from non-HIV related conditions.
  • Of all those dying from AIDS, 23% died<3 months after their initial diagnosis, reflecting late presentation.
  • In the current HAART era, 87% of patients who died from AIDS were extensively treated, reflecting HAART treatment failures due mostly to multiclass drug resistance (42%), inexorable disease progression despite ARV (32%), lack of ability or interest to be maintained on a lifelong HAART programme (21%) and, rarely, drug intolerance (<1%).
  • CONCLUSIONS: Deaths from AIDS-related causes have decreased significantly, but deaths from non-AIDS related conditions have increased, both as an absolute number of deaths and as a proportion of all deaths in HIV-infected patients.
  • The increasing age of the HIV population, and the increased mean CD4 count, increased proportion of intravenous drug users, increased hepatitis B virus and hepatitis C virus coinfection rate, and increased history of smoking seen in our population also influenced the mortality rate and causes of death.
  • These factors must also be considered in projecting future trends in mortality of an HIV-infected population.
  • [MeSH-major] HIV Infections / mortality
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / mortality. Alberta. Antiretroviral Therapy, Highly Active. Antiviral Agents / therapeutic use. Cause of Death / trends. Disease Progression. Drug Resistance, Multiple, Viral. Humans. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology. Mycobacterium avium-intracellulare Infection / mortality. Mycobacterium avium-intracellulare Infection / virology. Pneumonia, Pneumocystis / mortality. Pneumonia, Pneumocystis / virology. Socioeconomic Factors. Substance Abuse, Intravenous. Treatment Refusal


22. Dhir AA, Sawant SP: Malignancies in HIV: the Indian scenario. Curr Opin Oncol; 2008 Sep;20(5):517-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies in HIV: the Indian scenario.
  • PURPOSE OF REVIEW: India has the second largest number of HIV/AIDS patients in the world; however, studies done in the area of HIV-related malignancies are few.
  • With the availability of highly active antiretroviral therapy and treatment and prevention of opportunistic infections, an increase in life expectancy of HIV-infected individuals and an increase in HIV-related malignancies is expected.
  • The purpose of this review is to put forth the Indian scenario of HIV-related malignancies.
  • RECENT FINDINGS: About 2.5 million Indians have HIV/AIDS.
  • Non-Hodgkin's lymphoma and cervical cancer were found to occur in a higher proportion among the HIV-infected individuals in India as compared with non-HIV-infected individuals.
  • The incidence of AIDS-related primary central nervous system lymphoma is low in India.
  • Amongst the non-AIDS defining cancers anal cancer, testicular cancer, Hodgkin's disease, colon cancer and certain head and neck cancer sites in men and vaginal cancers among women were found to occur more frequently.
  • As India is a large country and geographically and culturally diverse, large-scale studies need to be done linking the regional cancer centres with the AIDS centres across the country to evaluate the exact burden of HIV-related malignancies.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / etiology. Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106653.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


23. Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, Rajadhyaksha S, Dinshaw KA: Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control; 2008 Mar;19(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of HIV/AIDS related cancers in India.
  • OBJECTIVE: To study the cancer pattern among HIV positive cancer cases.
  • METHOD: The study group included patients registered in the HIV Cancer clinic at the Tata Memorial Hospital (TMH), Mumbai, which is the largest tertiary referral cancer center in India.
  • We used the gender and age-specific proportions of each cancer site of the year 2002 that was recorded in the Hospital Cancer Registry to estimate an expected number of various cancer sites among HIV positive cancer patients during the period 2001-2005.
  • Increased proportion of non-Hodgkin's lymphoma (NHL) was observed (PIR in males = 17.1, 95%CI 13.33-21.84, females = 10.3, 95%CI 6.10-17.41).
  • In males, PIR was increased for anal cancer (PIR = 10.3, 95%CI 4.30-24.83), Hodgkin's disease, testicular cancer, colon cancer, and few head and neck cancer sites.
  • CONCLUSIONS: The absence of Kaposi's sarcoma and increased PIRs for certain non-AIDS defining cancers among HIV infected cancer cases indicates a different spectrum of HIV associated malignancies in this region.
  • The raised PIR for cervical cancer emphasizes the urgent need for screening programs for cervical cancer among HIV infected individuals in India.
  • [MeSH-major] HIV Infections. Neoplasms / epidemiology. Registries


24. Caimi PF, Barr PM, Berger NA, Lazarus HM: Non-Hodgkin's lymphoma in the elderly. Drugs Aging; 2010 Mar 01;27(3):211-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in the elderly.
  • The expansion of older population segments and the continuous increase in the incidence of non-Hodgkin's lymphoma (NHL) makes this group of neoplasms an important and growing problem.
  • Older NHL patients have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities.
  • The comprehensive geriatric assessment (CGA) is one multidisciplinary tool that has been applied successfully to older cancer patients and aids in identification of subjects who will or will not benefit from anti-neoplastic treatment.
  • Diffuse large B-cell lymphoma is an aggressive but potentially curable disease.
  • Highly selected individuals up to age 70 years may attain long-term survival benefit from autoHCT, although transplant-related mortality is higher than in younger patients.
  • [MeSH-major] Aging / physiology. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / physiopathology. Lymphoma, Non-Hodgkin / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]
  • [Cites] Blood. 2008 Jun 15;111(12 ):5486-95 [18390837.001]
  • [Cites] Clin Pharmacokinet. 2003;42(9):779-91 [12882586.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):25-29 [28140088.001]
  • [Cites] Oncology (Williston Park). 2007 Aug;21(9):1104-10 [17910313.001]
  • [Cites] Clin Pharmacokinet. 1996 Jul;31(1):47-64 [8827399.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3032-8 [15210738.001]
  • [Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):81-95 [15694186.001]
  • [Cites] Blood. 1990 Oct 1;76(7):1293-8 [2207307.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Cancer. 2008 May 15;112(10):2228-32 [18338745.001]
  • [Cites] Eur J Haematol. 2008 Feb;80(2):127-32 [18005385.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S1-8 [18752969.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] Eur J Cancer. 2003 May;39(7):870-80 [12706355.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3036-43 [19414675.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1726-33 [7602362.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1559-65 [12176870.001]
  • [Cites] Curr Treat Options Oncol. 2006 Jul;7(4):285-94 [16916489.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):357-9 [16648037.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1454-9 [15024027.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Oncology (Williston Park). 2007 Sep;21(10):1191-8; discussion 1198-1208, 1210 [17926798.001]
  • [Cites] Blood. 2005 May 15;105(10):3817-23 [15687232.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Feb;33(2):119-28 [10737373.001]
  • [Cites] Am J Geriatr Pharmacother. 2008 Aug;6(3):153-60 [18775390.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):44-56 [17242670.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52 [16084735.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1216-23 [17470451.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4302-11 [15381684.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Ann Oncol. 2009 Mar;20(3):520-5 [19074748.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3918-27 [14517188.001]
  • [Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]
  • [Cites] Leuk Lymphoma. 2008;49 Suppl 1:43-51 [18821432.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3158-67 [17634496.001]
  • [Cites] Br J Haematol. 2009 May;145(3):344-9 [19245430.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2982-4 [15210737.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 2:S43-9 [18284715.001]
  • [Cites] Bull Cancer. 2008 May 28;95 FMC Onco:F79-83 [18511372.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):273-85 [10439364.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]
  • [Cites] Am J Health Syst Pharm. 2007 Mar 15;64(6):652-60 [17353576.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] N Engl J Med. 1992 Oct 22;327(17):1209-15 [1406793.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1209-13 [19188674.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4390-8 [15994148.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1412-22 [10735888.001]
  • [Cites] Aging Clin Exp Res. 2005 Jun;17(3):181-5 [16110729.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2324-31 [17637813.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):957-64 [10800063.001]
  • [Cites] J Immunol. 2009 Jul 1;183(1):749-58 [19535640.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2105-12 [16606971.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):393-8 [6344979.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1607-14 [19255334.001]
  • [Cites] Clin Geriatr Med. 1997 May;13(2):251-63 [9115450.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2945-53 [9256139.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):1046 [8366915.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1323-33 [19041053.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Oct 08;(4):CD003189 [18843642.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3880-6 [16864854.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1984-92 [15668467.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]
  • [Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2677-84 [15591112.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):149-65 [18410453.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3214-9 [12874269.001]
  • [Cites] Cancer. 1976 Oct;38(4):1484-93 [791473.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):295-305 [3512783.001]
  • [Cites] Hematol Oncol. 1989 Sep-Oct;7(5):365-80 [2670728.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):398-405 [11529465.001]
  • [Cites] Blood. 2003 May 15;101(10):3840-8 [12531794.001]
  • [Cites] J Am Geriatr Soc. 2001 Dec;49(12):1691-9 [11844005.001]
  • [Cites] Br J Haematol. 2007 Jan;136(2):191-202 [17073892.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2554-9 [17515573.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):167-71 [8532901.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):47-56 [11707870.001]
  • [Cites] Leuk Lymphoma. 2008;49 Suppl 1:59-66 [18821434.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2269-71 [15166030.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2726-32 [7919385.001]
  • [Cites] Semin Oncol. 1993 Feb;20(1):43-9 [8475409.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1835-42 [15386331.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):116-21 [16971665.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):413-23 [12877668.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 1999 Jul 1;94(1):33-8 [10381495.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Ann Oncol. 2006 Sep;17 (9):1418-23 [16766582.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]
  • [Cites] N Engl J Med. 1998 Sep 24;339(13):900-5 [9744975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1219-27 [11728680.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Oct;8(10):1651-8 [18925856.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1327-30 [18349031.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] Ann Intern Med. 2002 Jan 15;136(2):144-52 [11790067.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):928-34 [16243446.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):579-87 [18242077.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301 [16985248.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2630-5 [14669282.001]
  • [Cites] Cancer Invest. 2007 Dec;25(8):766-75 [18058474.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3159-65 [18591554.001]
  • [Cites] Ann Oncol. 2008 Jun;19 Suppl 4:iv60-2 [18519407.001]
  • [Cites] Cancer Control. 2003 Nov-Dec;10(6):487-99 [14652525.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2407-14 [12805341.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Cancer Control. 1996 Oct;3(5 Suppl 1):5-14 [10765230.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):706-14 [17470738.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(6):593-9 [11319588.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1088-95 [15657401.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1582-9 [16575009.001]
  • [Cites] Lancet. 2009 Oct 31;374(9700):1512-20 [19767089.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):13-8 [9440717.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):257-62 [7612491.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):1037-49, x-xi [18954750.001]
  • [Cites] Blood. 1997 May 1;89(9):3129-35 [9129015.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2530-9 [7595704.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1S2):9-15 [28140221.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1202-8 [19204203.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):7-12 [17242666.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2352-8 [9667250.001]
  • [Cites] Leuk Lymphoma. 2009 Jan;50(1):47-53 [19152172.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1998-2005 [16206252.001]
  • [Cites] Ann Hematol. 2007 Feb;86(2):95-100 [17031689.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):675-81 [19701243.001]
  • [Cites] Curr Opin Oncol. 2008 Sep;20(5):502-8 [19106651.001]
  • [Cites] Bone Marrow Transplant. 2007 Nov;40(10):973-8 [17873917.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1302-10 [9317183.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1837-42 [18838474.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] Ann Intern Med. 1990 May 1;112(9):699-706 [2334082.001]
  • [Cites] Drugs Aging. 2003;20(10):737-59 [12875610.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):494-502 [11786579.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):329-36 [9640217.001]
  • [Cites] Gerontology. 1999 Sep-Oct;45(5):243-53 [10460985.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Haematologica. 2006 Jan;91(1):11-6 [16434365.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 2:67-71 [7515649.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):863-82, viii [18954741.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):27-34 [9440719.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):169-75 [17591563.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):613-26 [18687642.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2540-4 [16835383.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1492-501 [19224851.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):5-15 [12506163.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1469-79 [15084620.001]
  • [Cites] Ann Oncol. 1997 Jul;8(7):675-80 [9296221.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2687-93 [18625886.001]
  • [Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]
  • [Cites] Blood. 2002 Jun 15;99(12 ):4336-42 [12036859.001]
  • [Cites] Lancet Neurol. 2009 Jun;8(6):581-92 [19446277.001]
  • [Cites] Blood Rev. 2009 May;23(3):137-42 [18951668.001]
  • [Cites] Cancer Invest. 2006 Oct;24(6):593-600 [16982464.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1530-41 [16933332.001]
  • [Cites] Cancer Control. 2002 May-Jun;9(3):203-11 [12060818.001]
  • [Cites] Blood. 2001 Jan 15;97(2):404-9 [11154216.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3041-50 [12915593.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1544-52 [18285605.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):770-5 [11821460.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3803-9 [9850025.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3896-902 [19144985.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):511-8 [19075279.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4952-7 [18606983.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4144-52 [19168784.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 20210368.001).
  • [ISSN] 1179-1969
  • [Journal-full-title] Drugs & aging
  • [ISO-abbreviation] Drugs Aging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


25. Korać M, Brmbolić B, Salemović D, Ranin J, Stojsić Z, Jevtović D, Nikolić J: Diagnostic esophago-gastro-duodenoscopy (EGD) in patients with AIDS-related upper gastrointestinal abnormalities. Hepatogastroenterology; 2009 Nov-Dec;56(96):1675-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic esophago-gastro-duodenoscopy (EGD) in patients with AIDS-related upper gastrointestinal abnormalities.
  • BACKGROUND/AIMS: Gastrointestinal (GI) diseases are common among patients infected with human immunodeficiency virus (HIV), and may involve the entire GI tract.
  • The aim of the article is to investigate the prevalence of various upper gastrointestinal abnormalities in patients with AIDS.
  • METHODOLOGY: Diagnostic esophago-gastro-duodenoscopy (EGD) was performed in cohort of AIDS patients (total 186) including non-ART, mono and/or dual ART and HAART treated subgroups.
  • Thirty-nine patients (20.4%) had opportunistic infections/tumors including candida esophagitis, CMV esophagitis, CMV gastritis, gastric non-Hodgkin's lymphoma (NHL) and gastric cryptosporidiosis. H. pylori infection was present in 25.8% of patients, and majority (89.6%) had chronic non-atrophic gastritis.


26. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene; 2005 Mar 24;24(13):2121-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
  • The clinical application of rituximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has significantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular non-Hodgkin's lymphoma (NHL).
  • ARL (acquired immunodeficiency syndrome (AIDS)-related lymphoma) and non-ARL cell lines have been examined as in vitro model systems.
  • Downmodulation of the ERK1/2 and NF-kappa B pathways inhibits the transcriptional activity of AP-1 and NF-kappa B transcription factors, respectively, both of which lead to the downregulation of Bcl-(xL) (Bcl-2 related gene (long alternatively spliced variant of Bcl-x gene)) transcription and expression and sensitization to drug-induced apoptosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Signal Transduction / drug effects


27. Navarro JT, Vall-Llovera F, Mate JL, Morgades M, Feliu E, Ribera JM: Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART. Haematologica; 2008 Jan;93(1):149-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART.
  • We evaluated the frequency of primary central nervous system lymphoma and leptomeningeal involvement in systemic non-Hodgkin's lymphoma (NHL) in HIV-infected patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / prevention & control. Meninges / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Prognosis. Retrospective Studies. Time Factors


28. Tanaka PY, Calore EE: P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract; 2007;203(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
  • It still needs to be clarified whether P-gp expression has a significant impact on non-Hodgkin's lymphoma treatment response, but a poor outcome has been reported in patients with positive P-gp expression.
  • AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
  • In an attempt to determine a possible relationship between MDR and poor outcome in this population, histologic samples obtained from 45 non-Hodgkin's lymphoma HIV-infected patients without previous cytotoxic therapy were submitted to immunohistochemical analysis using monoclonal antibody C494 specific for the MDR-1 isoform of P-gp.
  • In patients having achieved complete remission, the median disease-free survival (DFS) was not reached; the mean DFS was 57.2 months with DFS rates of 72.9% in three years.
  • Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Res Pract. 2007;203(10):763
  • (PMID = 17157997.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


29. Mwakigonja AR, Kaaya EE, Mgaya EM: Malignant lymphomas (ML) and HIV infection in Tanzania. J Exp Clin Cancer Res; 2008;27:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphomas (ML) and HIV infection in Tanzania.
  • BACKGROUND: HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.
  • The ML frequency, pathogenicity, clinical patterns and possible association with AIDS in Tanzania, are not well documented impeding the development of preventive and therapeutic strategies.
  • METHODS: Sections of 176 archival formalin-fixed paraffin-embedded biopsies of ML patients at Muhimbili National Hospital (MNH)/Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania from 1996-2001 were stained for hematoxylin and eosin and selected (70) cases for expression of pan-leucocytic (CD45), B-cell (CD20), T-cell (CD3), Hodgkin/RS cell (CD30), histiocyte (CD68) and proliferation (Ki-67) antigen markers.
  • Available sera from 38 ML patients were screened (ELISA) for HIV antibodies.
  • RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD).
  • The ML tumors frequency increased from 0.42% (1997) to 0.70% (2001) and 23.7% of tested sera from these patients were HIV positive.
  • Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.
  • CONCLUSION: Malignant lymphomas apparently, increased significantly among diagnosed tumors at MNH between 1996 and 2001, predominantly among the young, HIV infected and AIDS patients.
  • The frequent aggressive clinical and histological presentation as well as the dominant B-immunophenotype and the HIV serology indicate a pathogenic association with AIDS.
  • Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology


30. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: state of the art and therapeutic challenges.
  • Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


31. Lu TH, Chang HJ, Chen LS, Chu MH, Ou NM, Jen I: Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan. J Formos Med Assoc; 2006 Jul;105(7):604-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan.
  • To assess the pattern of change in the causes of death among HIV/AIDS patients in Taiwan after the introduction of highly active antiretroviral therapy (HAART), national HIV/AIDS registry data were linked with cause of death and health insurance claims data from 1994 to 2002 for analysis.
  • Although HIV/AIDS remained the leading underlying cause of death among HIV/AIDS patients during the study period (552/752 = 73.4%), an increased proportion of deaths was due to non-HIV/AIDS causes (other infectious diseases, cancers, liver diseases, etc.) after the introduction of HAART in 1997.
  • Most AIDS-related conditions associated with death (cryptococcosis, cachexia/wasting, dementia/encephalopathy, etc.) decreased in frequency from 1998-2000 to 2001-2002.
  • Nonetheless, some AIDS-related conditions associated with death remained stable or increased in frequency, such as candidiasis, tuberculosis, and non-Hodgkin's lymphoma.
  • More effort is required to address the mental health of HIV/AIDS patients as a part of therapy.


32. Salemi M, Lamers SL, Huysentruyt LC, Galligan D, Gray RR, Morris A, McGrath MS: Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma. PLoS One; 2009 Dec 03;4(12):e8153
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma.
  • Despite highly active antiretroviral therapy (HAART), AIDS related lymphoma (ARL) occurs at a significantly higher rate in patients infected with the Human Immunodeficiency Virus (HIV) than in the general population.
  • HIV-infected macrophages are a known viral reservoir and have been shown to have lymphomagenic potential in SCID mice; therefore, there is an interest in determining if a viral component to lymphomagenesis also exists.
  • We sequenced HIV-1 envelope gp120 clones obtained post mortem from several tumor and non-tumor tissues of two patients who died with AIDS-related Non-Hodgkin's lymphoma (ARL-NH).
  • 1) high-resolution phylogenetic analysis showed a significant degree of compartmentalization between lymphoma and non-lymphoma viral sub-populations while viral sub-populations from lymph nodes appeared to be intermixed within sequences from tumor and non-tumor tissues, 2) a 100-fold increase in the effective HIV population size in tumor versus non-tumor tissues was associated with the emergence of lymphadenopathy and aggressive metastatic ARL, and 3) HIV gene flow among lymph nodes, normal and metastatic tissues was non-random.
  • The different population dynamics between the viruses found in tumors versus the non-tumor associated viruses suggest that there is a significant relationship between HIV evolution and lymphoma pathogenesis.
  • Moreover, the study indicates that HIV could be used as an effective marker to study the origin and dissemination of lymphomas in vivo.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Genetics. 2006 Apr;172(4):2665-81 [16489234.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1369-75 [17128264.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):272-9 [17324334.001]
  • [Cites] PLoS Comput Biol. 2007 Feb 16;3(2):e29 [17305421.001]
  • [Cites] PLoS One. 2007;2(9):e950 [17895991.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]
  • [Cites] Retrovirology. 2007;4:87 [18053211.001]
  • [Cites] BMC Evol Biol. 2007;7:214 [17996036.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):285-93 [19308068.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] Genetics. 2000 Jul;155(3):1429-37 [10880500.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]
  • [Cites] Mol Biol Evol. 2001 Jun;18(6):1001-13 [11371589.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2310-4 [11743192.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]
  • [Cites] Science. 2004 Jan 16;303(5656):327-32 [14726583.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]
  • [Cites] Genetics. 1989 Nov;123(3):603-13 [2599370.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Mol Biol Evol. 2005 May;22(5):1185-92 [15703244.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • (PMID = 19997510.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA096230-06; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA009126; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA09126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120
  • [Other-IDs] NLM/ PMC2780293
  •  go-up   go-down


33. Akanmu AS: AIDS-associated malignancies. Afr J Med Med Sci; 2006 Dec;35 Suppl:57-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated malignancies.
  • A number of immunodeficiency states--both inherited (such as agammaglobulinaemia, Bloom's syndrome, hereditary telangiectasia) and acquired (e.g. immunosuppressive therapy) have been associated with varieties of cancers.
  • HIV induces more profound immunodeficiency state and it should not be difficult to imaging why cancer diagnosis is made in over 40% of HIV infected patients.
  • Impairment of normal function of natural killer cells as a result of lack of helper signals from CD4+ T-lymphocytes may be a major mechanism of increased susceptibility to cancer development in HIV infected patients.
  • Three neoplastic diseases are associated so commonly with HIV infection that each of them has become recognized as an AIDS defining illness.
  • These are Kaposi's Sarcoma (KS), Non-Hodgkin's Lymphoma (NHL) and Cervical Carcinoma.
  • Both KS and NHL were recognized as AIDS associated cancers from the onset of the epidemic in 1981 but carcinoma of the cervix became AIDS defining in 1993.
  • [MeSH-major] HIV. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050776.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 114
  •  go-up   go-down


34. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
  • PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
  • CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.
  • Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


35. Orem J, Fu P, Ness A, Mwanda WO, Remick SC: Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease. East Afr Med J; 2005 Sep;82(9 Suppl):S144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease.
  • OBJECTIVES: To determine the effectiveness of an oral combination chemotherapy regimen administered to patients with AIDS-associated Hodgkin's disease.
  • MAIN OUTCOME MEASURES: Clinical demographic variables, peripheral blood counts, serum chemistries, CD4 lymphocyte count, histopathological subtype of Hodgkin's disease were identified for all patients, who were staged according to Ann Arbor criteria.
  • CONCLUSIONS: This feasibility study demonstrates acceptable tolerance and excellent clinical activity of oral combination chemotherapy in patients with AIDS-associated Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619690.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


36. Iwahashi N, Nakatani S, Kakuchi H, Yamagishi M, Fukuchi K, Ishida Y, Hirooka K, Koretsune Y, Ueta C, Shirasaka T, Kitakaze M: Cardiac tumor as an initial manifestation of acquired immunodeficiency syndrome. Circ J; 2005 Feb;69(2):243-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cardiac tumor was the first manifestation of acquired immunodeficiency syndrome (AIDS) in a female patient in a state of severe immunodeficiency caused by human immunodeficiency virus (HIV) infection.
  • The extensive cardiac and extracardiac involvement shown by various imaging modalities, including echocardiography and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), suggested that she was in the critical stage of non-Hodgkin's lymphoma (NHL).
  • AIDS was treated by highly active-antiretroviral therapy and the NHL was treated by a combination of rituximab-cyclophosphamide-vincristine-doxorubicine-predonisolone.
  • Generally, an AIDS-related cardiac tumor tends to be diagnosed at the late stage of the disease because of its nonspecific clinical findings, resulting in an extremely poor prognosis.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heart Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / etiology


37. Buonaguro L, Petrizzo A, Tornesello M, Napolitano M, Martorelli D, Castello G, Beneduce G, De Renzo A, Perrella O, Romagnoli L, Sousa V, De Re V, Dolcetti R, Buonaguro FM: Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med; 2010;8:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.
  • Hepatitis C virus (HCV) is one of the major risk factors for chronic hepatitis, which may progress to cirrhosis and hepatocellular carcinoma, as well as for type II mixed cryoglobulinemia (MC), which may further evolve into an overt B-cell non-Hodgkin's lymphoma (NHL).
  • It has been previously shown that B-cell receptor (BCR) repertoire, expressed by clonal B-cells involved in type II MC as well as in HCV-associated NHL, is constrained to a limited number of variable heavy (VH)- and light (VL)-chain genes.

  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):211-6 [10861476.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3578-84 [11071657.001]
  • [Cites] J Clin Lab Anal. 2002;16(1):40-6 [11835530.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):571-80 [12353944.001]
  • [Cites] Turk J Gastroenterol. 2003 Mar;14(1):7-11 [14593531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]
  • [Cites] Cell Res. 2004 Jun;14(3):251-6 [15225419.001]
  • [Cites] J Exp Med. 1989 Sep 1;170(3):827-45 [2504877.001]
  • [Cites] Ann Intern Med. 1992 Oct 1;117(7):573-7 [1326246.001]
  • [Cites] J Exp Med. 1993 Sep 1;178(3):1041-8 [8102388.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3701-4 [8260706.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1109-18 [8145033.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):211-22 [7516408.001]
  • [Cites] J Intern Med. 1994 Jul;236(1):31-6 [8021570.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4638-45 [8977256.001]
  • [Cites] J Hepatol. 1997 Mar;26(3):471-8 [9075651.001]
  • [Cites] Clin Rev Allergy Immunol. 1997 Spring;15(1):97-119 [9209804.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Mediators Inflamm. 1998;7(4):295-7 [9792341.001]
  • [Cites] Science. 1998 Oct 30;282(5390):938-41 [9794763.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1666-73 [10415073.001]
  • [Cites] J Hepatol. 2005 Jan;42(1):61-7 [15629508.001]
  • [Cites] J Virol. 2005 Mar;79(5):3052-62 [15709025.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 May;17(5):477-83 [15827436.001]
  • [Cites] J Infect Dis. 2005 Aug 1;192(3):497-503 [15995965.001]
  • [Cites] J Virol. 2006 Sep;80(18):9134-43 [16940524.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1205-7 [17383452.001]
  • [Cites] World J Gastroenterol. 2007 May 7;13(17):2467-78 [17552031.001]
  • [Cites] Clin Vaccine Immunol. 2007 Sep;14(9):1127-37 [17634507.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1344-56 [17942751.001]
  • [Cites] BMC Bioinformatics. 2008;9 Suppl 2:S5 [18387207.001]
  • [Cites] Autoimmun Rev. 2008 Jun;7(6):468-72 [18558364.001]
  • [Cites] Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S39-47 [18570753.001]
  • [Cites] J Virol. 2009 Jan;83(1):304-13 [18945779.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):116-25 [19029902.001]
  • [Cites] J Exp Med. 2008 Dec 22;205(13):3119-31 [19047440.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Aug;7(8):900-5 [19362606.001]
  • [Cites] AIDS Res Hum Retroviruses. 2009 Aug;25(8):819-22 [19630502.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):675-81 [19701243.001]
  • [Cites] FEBS Lett. 2009 Sep 17;583(18):3004-8 [19665024.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1173:152-60 [19758144.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):223-31 [7516409.001]
  • (PMID = 20170491.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines; 0 / Immunoglobulin Idiotypes; 0 / Immunoglobulin Variable Region; 0 / Receptors, Antigen, B-Cell; 0 / Viral Vaccines
  • [Other-IDs] NLM/ PMC2839974
  •  go-up   go-down


38. Ramírez-Olivencia G, Valencia-Ortega ME, Martin-Carbonero L, Moreno-Celda V, González-Lahoz J: [Malignancies in HIV infected patients: study of 139 cases]. Med Clin (Barc); 2009 Nov 21;133(19):729-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignancies in HIV infected patients: study of 139 cases].
  • BACKGROUND AND OBJECTIVE: Since the introduction of highly active antiretroviral therapy (HAART), the natural history of HIV infection has been altered by an increasing survival.
  • Following this, neoplastic diseases have become more common in HIV positive patients.
  • The purpose of this study was to describe the types of tumor, clinical features and prognosis of HIV infected patients with malignant diseases.
  • Information was collected on age, sex, risk factors for HIV, HBV/HCV coinfection, malignancies, diagnosis of AIDS, viral load and CD4 cell counts at diagnosis, antiretroviral therapy and mortality.
  • A total of 139 HIV-infected patients were identified who had at least one malignancy.
  • RESULTS: Types of malignancy were Kaposi's Sarcoma (n=43, 30.9%); non-Hodgkin lymphoma (n=42, 30.2%); gynecologic malignancy (n=16, 11.5%); Hodgkin's disease (n=15, 10.8%); hepatocellular carcinoma (n=7, 5%) and others (n=16, 11.5%).
  • Risk factor for HIV was MSM (n=64;46%), IDUs (n=48; 34.5%) and heterosexual (n=26; 18.7%).
  • CONCLUSIONS: Increased survival of HIV-infected patients receiving HAART makes it possible the development of secondary tumors and AIDS- unrelated malignancies, sometimes related to another virus.
  • [MeSH-major] HIV Infections / complications. Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880148.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


39. Phatak UA: Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma. Indian J Med Paediatr Oncol; 2009 Oct;30(4):153-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma.
  • Immune Reconstitution syndrome following antiretroviral therapy is common in HIV/AIDS patients due to boosting of immunity.
  • A case is reported here wherein AIDS-related Non-Hodgkin's lymphoma patient received CHOP regimen and antiretroviral therapy.


40. Noy A: Update in HIV lymphoma. Curr Opin Oncol; 2006 Sep;18(5):449-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update in HIV lymphoma.
  • PURPOSE OF REVIEW: Despite the control of HIV infection in industrialized nations, individuals infected with HIV remain at increased risk of malignancies.
  • Lymphoma is the most common HIV-associated malignancy in these countries.
  • RECENT FINDINGS: Investigators continue to demonstrate that HIV-associated non-Hodgkin's lymphoma remains a significant problem, even in the era of highly active antiretroviral therapy.
  • The majority of work has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising, and rituximab an area of investigation.
  • The latter improves complete response rates, but is associated with an increased incidence of infections.
  • Biological insights have been gained into the spectrum of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and include further work on virological co-infections.
  • SUMMARY: The outcome for individuals infected with HIV and developing non-Hodgkin's lymphoma and Hodgkin's disease continues to improve as insights into the pathophysiology and treatment advance.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894292.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 45
  •  go-up   go-down


41. Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May T, Chêne G, Mortality 2000 study group: Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol; 2005 Feb;34(1):121-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
  • BACKGROUND: In the era of highly active antiretroviral therapy (HAART) mortality has decreased substantially among human immunodeficiency virus (HIV)-infected people with access to HAART, but there are concerns regarding co-morbidities and adverse effects of HAART, which may impair vital prognosis.
  • The Mortality 2000 study examined the causes of death in HIV-infected adults at a national level in France in the year 2000.
  • METHODS: All French hospital wards known to be involved in the management of HIV infection were asked to notify prospectively the deaths that occurred in 2000 among HIV-infected adults.
  • The main underlying causes of death were AIDS-related (47%, non-Hodgkin's lymphoma: 23%), viral hepatitis (11%, hepatitis C: 9%, hepatitis B: 2%), cancer not related to AIDS or hepatitis (11%), cardiovascular disease (7%), bacterial infections (6%), suicide (4%), and adverse effect of antiretroviral treatments (1%).
  • Among AIDS-related deaths, HIV infection had been diagnosed recently in 20%.
  • Smoking was recorded in 72% of cancer-related deaths and alcohol consumption in 54% of hepatitis-related deaths.
  • Among non-HIV related deaths between 25 and 64 years, the proportion of infectious diseases (including HCV and HBV-related deaths) was higher in HIV-infected adults than in the general population.
  • CONCLUSIONS: Improved strategies for detecting HIV infection before AIDS-defining complications occur are needed in the era of HAART.
  • The prevention of non-AIDS related cancers, especially lung cancer, the management of non-Hodgkin's lymphoma, and of viral hepatitis are also important priorities.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / mortality. Hepatitis, Viral, Human / mortality. Neoplasms / mortality


42. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, Ramos JC, Luz E, Pedroso C, Manrique M, Toomey NL, Brites C, Dittmer DP, Harrington WJ Jr: EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res; 2008 Mar 1;68(5):1436-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression pattern of these miRNAs in clinical samples of EBV-associated non-Hodgkin's lymphomas is unknown.
  • We analyzed five primary "endemic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I latency BL lines, a type III latency line, three EBV(+) primary effusion lymphomas (PEL), and three AIDS-related diffuse large B-cell lymphomas (DLBCL) for expression of EBV-encoded miRNAs.
  • EBV-encoded miRNAs are expressed in primary lymphomas classically linked to the virus and are associated with the viral latency status.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Microbiol. 2000;54:19-48 [11018123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9 [17911266.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1098-104 [12219084.001]
  • [Cites] J Gen Virol. 2003 Apr;84(Pt 4):949-57 [12655096.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Virology. 2004 May 20;323(1):141-52 [15165826.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30219-27 [15150261.001]
  • [Cites] RNA. 2004 Aug;10(8):1165-73 [15272116.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8058-62 [1325642.001]
  • [Cites] J Virol. 1993 Jun;67(6):3182-90 [8388496.001]
  • [Cites] J Virol. 1995 Feb;69(2):1132-41 [7815492.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1493-501 [7632957.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Hum Pathol. 1997 Dec;28(12):1408-14 [9416698.001]
  • [Cites] Science. 1998 Apr 10;280(5361):248-53 [9535648.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):2009-21 [9625760.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1290-7 [15741182.001]
  • [Cites] Science. 2005 Apr 22;308(5721):557-60 [15845854.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):682-6 [15931223.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):343-51 [16000952.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] Development. 2005 Nov;132(21):4645-52 [16224044.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):e182 [16314296.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Mamm Genome. 2006 Mar;17(3):189-202 [16518686.001]
  • [Cites] Curr Opin Genet Dev. 2006 Apr;16(2):203-8 [16503132.001]
  • [Cites] Vaccine. 2006 Apr 5;24(15):2966-74 [16503368.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] J Virol. 2007 Sep;81(18):9967-75 [17626073.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):635-43 [12115495.001]
  • (PMID = 18316607.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA082274; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA70058; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA121935; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935; United States / NIDCR NIH HHS / DE / DE018304-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BHRF1 protein, Human herpesvirus 4; 0 / CXCL11 protein, human; 0 / Chemokine CXCL11; 0 / MicroRNAs; 0 / Oligonucleotides, Antisense; 0 / Viral Proteins; EC 3.1.- / Ribonucleases
  • [Other-IDs] NLM/ NIHMS191351; NLM/ PMC2855641
  •  go-up   go-down


43. Adler DH: The impact of HAART on HPV-related cervical disease. Curr HIV Res; 2010 Oct;8(7):493-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of HAART on HPV-related cervical disease.
  • PURPOSE OF REVIEW: highly active antiretroviral therapy (HAART) has had an unequivocally positive impact on morbidity and mortality in HIV-infected individuals.
  • These benefits have clearly extended to some HIV-related malignancies, including Kaposi's sarcoma and non-Hodgkin's lymphoma.
  • The objective of this review is to summarize the last ten years of registry-based and clinical research into the impact of HAART on human papillomavirus (HPV) related cervical disease.
  • RELEVANT FINDINGS: compared to their HIV-uninfected counterparts, HIV-infected women have an increased prevalence of HPV infection, increased risk of progression of HPV-related cervical disease, and an increased risk of invasive cervical cancer.
  • While the partial immune reconstitution afforded by HAART might be expected to decrease susceptibility to HPV infection and cervical disease, the local effects of improved immunosurveillance on the cervix are uncertain and the increased longevity of patients on HAART may increase risk of exposure to HPV and provide the time required for progression of cervical disease.
  • Clinical research on the subject, however, has produced conflicting evidence with regards to both the effect of HAART on HPV infection and its impact on cervical disease progression/regression.
  • Furthermore, clinical research has not shown a clear benefit of HAART in decreasing HPV-related cervical disease in HIV-infected women.
  • A better understanding of this subject will have an impact on cervical disease surveillance practices.


44. Rafaniello Raviele P, Pruneri G, Maiorano E: Plasmablastic lymphoma: a review. Oral Dis; 2009 Jan;15(1):38-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: a review.
  • Plasmablastic lymphoma (PBL) has been recently characterised as an aggressive subtype of non-Hodgkin's lymphoma, most frequently arising in the oral cavity of HIV-infected patients.
  • Similar to other types of AIDS-related lymphomas, there is evidence that Epstein-Barr virus and Kaposi-sarcoma associated Human Herpes Virus 8 may play a relevant role in the pathogenesis of PBL.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939960.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / SDC1 protein, human; 0 / Syndecan-1
  • [Number-of-references] 54
  •  go-up   go-down


45. Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R: Cancer biomarkers in HIV patients. Curr Opin HIV AIDS; 2010 Nov;5(6):531-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer biomarkers in HIV patients.
  • PURPOSE OF REVIEW: In this review, we update investigations related to cancer biomarkers in HIV-infected populations.
  • RECENT FINDINGS: CD4 lymphocyte count is associated with primary central nervous system lymphoma (PCNSL), systemic non-Hodgkin's lymphoma (NHL) (except perhaps for Burkitt lymphoma), Kaposi's sarcoma, cervical cancer, and anal cancer.
  • HIV load is associated with Burkitt lymphoma and systemic NHL (but not PCNSL), with Kaposi's sarcoma and with anal cancer.
  • CD40 ligand incorporated into the HIV envelope and expression of activation-induced cytidine deaminase may help explain the relationship between HIV load and Burkitt lymphoma.
  • Genetic polymorphisms have been identified that are linked to lymphoma in HIV patients.
  • Cytokines and related molecules (IL10, sCD30) may identify patients at high risk for NHL.
  • EBV and Kaposi's sarcoma-associated herpesvirus (KSHV) have not yet emerged as especially promising markers of risk for either lymphoma or Kaposi's sarcoma.
  • SUMMARY: CD4 lymphocyte count, HIV load, germline genetic polymorphisms, cytokine and related molecules, and immunoglobulin light chains all show increasing promise as biomarkers of malignancy in HIV patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1396-7; author reply 1397-8 [15494920.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):760-4 [15721423.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] J Clin Virol. 2006 Aug;36(4):258-63 [16762591.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Int J Infect Dis. 2007 Mar;11(2):172-8 [16931088.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] PLoS Med. 2007 Mar 27;4(3):e96 [17388662.001]
  • [Cites] J Clin Virol. 2008 Aug;42(4):433-6 [18455472.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):427-9 [19322036.001]
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2496-502 [19349542.001]
  • [Cites] Haematologica. 2009 Jun;94(6):875-80 [19336735.001]
  • [Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2354; author reply 2354-5 [19745076.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2730-2 [19638620.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22 [19770804.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9 [19654554.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91 [19835968.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):773-9 [20048176.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):497-506 [20038229.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1514-9 [20177022.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1025-33 [20299965.001]
  • [Cites] Cancer Causes Control. 2010 May;21(5):759-69 [20087644.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]
  • [Cites] Sex Transm Dis. 2010 May;37(5):311-5 [20065890.001]
  • [Cites] J Natl Cancer Inst. 2010 Jun 2;102(11):784-92 [20442214.001]
  • [Cites] BMC Cancer. 2010;10:278 [20537184.001]
  • [Cites] Clin Infect Dis. 2010 Aug 1;51(3):342-9 [20572760.001]
  • [Cites] PLoS One. 2010;5(7):e11448 [20625427.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 20978397.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947-05; United States / NCI NIH HHS / CA / CA096888-05S2; United States / NCI NIH HHS / CA / UO1 CA 121947; United States / NCI NIH HHS / CA / P50 CA096888-05S2; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS274983; NLM/ PMC3055562
  •  go-up   go-down


46. Lee SM, Buchler T, Bomanji J, Ramsay A, Edwards SG: Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult. AIDS; 2008 Jan 2;22(1):159-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Disease Progression. Fluorodeoxyglucose F18 / metabolism. Humans. Male. Positron-Emission Tomography / methods. Thymus Gland / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090408.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antibiotics, Antineoplastic; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


47. Corti M, Villafañe MF, Souto L, Schtirbu R, Narbaitz M, Soler Mde D: Burkitt's lymphoma of the duodenum in a patient with AIDS. Rev Soc Bras Med Trop; 2007 May-Jun;40(3):338-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of the duodenum in a patient with AIDS.
  • Non-Hodgkin's lymphoma of B-cell type is the second most common neoplasm after Kaposi's sarcoma, among patients with human immunodeficiency virus infection.
  • Most non-Hodgkin's lymphoma cases that are associated with acquired immunodeficiency syndrome involve extranodal sites, especially the digestive tract and the central nervous system.
  • We report a case of primary lymphoma of the duodenum in a patient with AIDS.
  • A complete diagnostic study including histological, immunohistochemical and virological analyses showed high-grade B-cell Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Duodenal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653472.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


48. Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martínez-Maza O: Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol; 2006;27(4):187-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma.
  • CD30, first described as the Ki antigen on malignant B cells in Hodgkin's lymphoma, is also expressed on normal activated B and T cells.
  • In a cross-sectional study utilizing archived sera at a time point close to but preceding a diagnosis of acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin's B cell lymphoma, AIDS lymphoma subjects (n = 49) showed elevated mean levels of sCD30 compared to controls with AIDS but no malignancy (n = 44, p < 0.01), HIV-infected but relatively healthy (n = 47, p < 0.001), or HIV-seronegative controls (n = 44, p < 0.001).
  • Serum sCD30 was significantly correlated to serum levels of the B cell cytokines interleukin-6 (IL-6), IL-10, and sCD23, but only among lymphoma subjects (p < or = 0.05).
  • Correlations between sCD30 and other markers of immune system activation were seen among all HIV-infected subjects (sCD27, sCD44, CXCL13, p < 0.05).
  • These observations suggest that sCD30, especially in combination with other immune system molecules, could be an important biomarker for an immune system environment conducive to B cell hyperactivation and the development of AIDS-associated B cell lymphoma.
  • [MeSH-major] Antigens, CD30 / blood. Lymphoma, AIDS-Related / immunology. Lymphoma, B-Cell / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / physiopathology. Antigens, CD / blood. Biomarkers. CD4 Lymphocyte Count. HIV Infections / physiopathology. Humans. Interleukins / blood. Predictive Value of Tests. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16651853.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NIAID NIH HHS / AI / UO1-AI-37984
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; 0 / Biomarkers; 0 / Interleukins
  •  go-up   go-down


49. Tisdale G, Mahadevan A, Matthews RH: T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion. Oncologist; 2005 Apr;10(4):292-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion.
  • Primary T-cell non-Hodgkin's lymphoma (NHL) occurring in the context of acquired immune deficiency syndrome (AIDS) is uncommon.
  • Although typical in some respects, the case is, in other ways, somewhat unusual for an AIDS-related NHL (ARL); ARL tends to be B cell and advanced stage and our case was T cell and stage IE.
  • In addition, the patient suffered from concomitant cirrhosis related to hepatitis C.
  • Chemotherapeutic options for ARL were limited early in the AIDS epidemic due to poor tolerability.
  • Although this has largely been mitigated by the advent of highly active antiretroviral therapy, our patient eventually suffered complications of chemotherapy, apparently related more to his liver disease than to either his lymphoma or AIDS, that ultimately brought about his demise.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Hepatitis C / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, T-Cell / diagnosis. Rectal Neoplasms / diagnosis


50. Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU: Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma; 2005 Feb;46(2):207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
  • Non-Hodgkin's lymphoma is an AIDS-defining disease.
  • We collected data of 214 cases of AIDS-related Lymphoma (ARL) treated at our centre from January 1984 until May 2003 and analysed them using the Kaplan-Meier-, log rank- and Cox proportional hazard-model.
  • The incidence of AIDS-related primary CNS lymphomas (PCNSL) took a comparable, yet more pronounced development.
  • Using the univariate Kaplan-Meier analysis prolonged survival was significantly associated with the achievement of a complete remission as well as with a favourable virological response to HAART.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621803.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


51. Fleisch F, Reinhart WH, Brand B, Berger C: Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma. Swiss Med Wkly; 2005 Apr 30;135(17-18):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma.
  • Immunocompromised patients are at risk of developing Epstein-Barr virus (EBV)-related lymphoproliferative disorders.
  • Quantitative determination of serum EBV DNA permits early diagnosis of an AIDS-related non-Hodgkin's lymphoma, and surveillance of treatment response and/or relapse, and thus may be a useful tool to monitor disease activity.
  • [MeSH-major] DNA, Viral / blood. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Anti-HIV Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Prednisone / administration & dosage. Switzerland. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15965829.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / DNA, Viral; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


52. Tserenpuntsag B, Kołacińska A, Jabłonowska E: [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)]. Przegl Epidemiol; 2007;61(3):529-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
  • [Transliterated title] Nowotwory zwiazane z AIDS w erze skojarzonego leczenia antyretrowirusowego (HAART).
  • HIV infected subjects are at increased risk of developing cancer and the risk seems to be directly associated with the level of immunodeficiency.
  • Kaposi's sarcoma, Non-Hodgkin's lymphoma (ARL) and invasive cervical cancer are the most common AIDS-defining malignancies.
  • HAART widely used since 1996 changed the natural process of HIV infection by aggressively suppressing viral replication and progress of HIV disease.
  • It significantly reduced the incidence of AIDS associated events and deaths and even changed treatment regimens ofAIDS associated cancers.
  • HAART allows the use of standard-dose chemotherapies for NON-Hodgkin lymphoma in HIV infected pacients and same treatment regimen for invasive cervical cancer in infected patients as non-infected patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology. Sarcoma, Kaposi / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Female. Humans. Male. Remission Induction. Treatment Outcome


53. Hernàndez DE, Hernàndez AE: Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor. Eur J Cancer Care (Engl); 2006 Dec;15(5):493-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
  • The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin's lymphoma (NHL) patients is very expensive in developing countries.
  • We treated 22 HIV-associated diffuse NHL patients with standard-dose CHOP and used G-CSF after an episode of febrile neutropenia until neutrophil count reached 1000/mm3.
  • The clinical response was: complete response (36%), partial response (32%), stable disease (14%) and progression (18%).
  • There were no toxicity-related deaths.
  • Our experience showed that we can treat HIV-related NHL patients with full-dose CHOP, achieve good responses and have an acceptable toxicity profile, with the use of G-CSF as needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177909.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


54. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematologic complications of HIV infection.
  • Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies.
  • Thrombotic thrombocytopenic purpura and thrombosis resulting from protein S deficiency are relatively rare complications of HIV in the United States in patients taking HAART, but are frequent in the developing world where these drugs are not available.
  • Hodgkin's and non-Hodgkin's lymphoma are still problematic in patients with advanced disease with high viral loads.
  • This review will examine and discuss the diagnosis and management of the hematologic complications of HIV.
  • [MeSH-major] HIV Infections / complications. Hematologic Diseases / etiology
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down


55. Lim ST, Levine AM: Non-AIDS-Defining Cancers and HIV Infection. Curr Infect Dis Rep; 2005 May;7(3):227-234
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-Defining Cancers and HIV Infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities such as malignancies have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.
  • Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies should be treated with similar approaches to those of their counterparts in the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 15847726.001).
  • [ISSN] 1523-3847
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Visani G, Isidori A: Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. Expert Rev Anticancer Ther; 2009 Mar;9(3):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.
  • Anthracyclines, including doxorubicin, are widely used in the treatment of B-cell non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Humans. Liposomes. Lymphoma, AIDS-Related / drug therapy. Middle Aged. Prednisolone / administration & dosage. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275512.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  • [Number-of-references] 31
  •  go-up   go-down


57. Hassan A, Kreisel F, Gardner L, Lewis JS Jr, El-Mofty SK: Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status. Head Neck Pathol; 2007 Dec;1(2):150-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status.
  • Plasmablastic lymphoma (PBL) is a rare acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma (AIDS-NHL), with predilection for the mucosa of oral cavity.
  • It usually has a plasmablastic morphology, expressing plasma cell-associated antigens with weak or absent expression of B-cell-associated markers.
  • For the first time we report a case of AIDS-related PBL that, by fluorescence in situ hybridization (FISH), shows a c-myc gene rearrangement.
  • Although current literature suggests that most cases of c-myc gene rearranged AIDS-NHL are Burkitt's lymphoma, our case has an immunophenotype characteristic for PBL.
  • The concurrent B-cell immunophenotype of BCL-6(-)/CD138(+)/MUM-1(+) also suggests a post-germinal center B-cell origin of this lymphoma.
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Mouth Neoplasms / pathology. Proto-Oncogene Proteins c-myc / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Cancer. 2005 Jun 25;105(3):139-44 [15803491.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):198-206 [16037778.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):392-404 [12055673.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1993 Jan 1;81(1):166-76 [8380252.001]
  • [Cites] Blood. 1993 Jul 15;82(2):552-63 [8392399.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):67-82 [9044511.001]
  • (PMID = 20614267.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ PMC2807524
  • [Keywords] NOTNLM ; Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma / Immunoglobulin variable heavy chain hypermutation status / Plasmablastic lymphoma / c-myc gene rearrangement
  •  go-up   go-down


58. Spina M, Simonelli C, Tirelli U: Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol; 2007 Feb 20;25(6):e7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / therapeutic use. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Drug Administration Schedule. Female. Humans. Male. Prednisone / therapeutic use. Prognosis. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • (PMID = 17308261.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


59. Wang J, Ozzard A, Nathan M, Atkins M, Nelson M, Gazzard B, Bower M: The significance of Epstein-Barr virus detected in the cerebrospinal fluid of people with HIV infection. HIV Med; 2007 Jul;8(5):306-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of Epstein-Barr virus detected in the cerebrospinal fluid of people with HIV infection.
  • INTRODUCTION: Epstein-Barr virus (EBV) is detected in the cerebrospinal fluid (CSF) in people with HIV infection who develop primary cerebral lymphoma (PCL).
  • METHODS: Ninety-eight HIV-positive patients had lumbar punctures performed and polymerase chain reaction (PCR) for EBV was undertaken on the CSF.
  • Thirty-eight patients had non-Hodgkin's lymphoma (NHL), including four with PCL.
  • RESULTS: EBV was detected in the CSF in three of four patients (75%) with PCL, one of three (33%) with systemic lymphoma and meningeal involvement, and four of 31 (13%) with systemic lymphoma and no meningeal disease.
  • Seven of 60 patients (12%) without lymphoma were CSF EBV-positive.
  • CONCLUSION: EBV was detected in up to 12% of patients with neurological symptoms but without lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / cerebrospinal fluid. HIV / growth & development. HIV Infections / cerebrospinal fluid. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / diagnosis


60. Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips AN, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B, Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels M, Sabin CA, UK CHIC Steering Committee: CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica; 2009 Jun;94(6):875-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.
  • Since the introduction of highly active antiretroviral therapy, there has been a decline in the incidence of non-Hodgkin's lymphoma among HIV-infected individuals.
  • We described trends in the incidence of systemic non-Hodgkin's lymphoma in the UK CHIC Study from 1996-2006 and evaluated the association between immunosuppression and development of systemic non-Hodgkin's lymphoma: 286/23,155 (1.2%) individuals developed an AIDS-defining lymphoma (258 systemic).
  • Younger age, receipt of highly active antiretroviral therapy and later calendar year were all independently associated with a reduced risk of systemic non-Hodgkin's lymphoma.
  • A lower latest CD4 count was strongly associated with systemic non-Hodgkin's lymphoma, in patients who had (RR per log(2)(cells/mm(3)) higher: 0.62) and had not (0.70) received highly active antiretroviral therapy.
  • Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma.
  • [MeSH-major] HIV Infections / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Exp Med Biol. 2001;495:205-12 [11774568.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Clin Infect Dis. 2003 Nov 1;37(9):1244-9 [14557970.001]
  • [Cites] HIV Med. 2004 Mar;5(2):115-24 [15012652.001]
  • [Cites] AIDS. 2004 Mar 5;18(4):673-81 [15090773.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] JAMA. 2006 Aug 16;296(7):827-43 [16905788.001]
  • [Cites] HIV Med. 2006 Nov;7(8):487-503 [17105508.001]
  • [Cites] PLoS Med. 2007 Mar 27;4(3):e96 [17388662.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] HIV Med. 2008 Jul;9 Suppl 2:34-40 [18557871.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):142-4 [12455069.001]
  • (PMID = 19336735.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / G0600337; United Kingdom / Medical Research Council / / G0000199; United Kingdom / Medical Research Council / / MC/ U122886351; United Kingdom / Medical Research Council / / G0200585; United Kingdom / Medical Research Council / / G0600337
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2688582
  • [Investigator] Bower M; Fisher M; Hill T; Reeves I; Walsh J; Orkin C; Phillips AN; Bansi L; Gilson R; Easterbrook P; Johnson M; Gazzard B; Leen C; Pillay D; Schwenk A; Anderson J; Porter K; Gompels M; Sabin CA
  •  go-up   go-down


61. Krause J: AIDS-related non-Hodgkin's lymphomas. Microsc Res Tech; 2005 Nov;68(3-4):168-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related non-Hodgkin's lymphomas.
  • This work reviews the current status of non-Hodgkin's lymphoma (NHL) in HIV infected patients.
  • HIV infection remains at significantly increased risk for the development of NHL.
  • A number of genetic abnormalities have been found but additional studies are necessary to understand the etiology and pathogenesis of NHL in the setting of HIV infection.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, AIDS-Related / pathology. Lymphoma, Non-Hodgkin / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16276515.001).
  • [ISSN] 1059-910X
  • [Journal-full-title] Microscopy research and technique
  • [ISO-abbreviation] Microsc. Res. Tech.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


62. Corti M, Villafañe MF, Trione N, Schtirbu R, Narbaitz M: Primary pulmonary AIDS-related lymphoma. Rev Inst Med Trop Sao Paulo; 2005 Jul-Aug;47(4):231-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary AIDS-related lymphoma.
  • Extranodal involvement is common in lymphomas associated with human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS).
  • However, primary pulmonary AIDS-related non-Hodgkin's lymphoma is very rare and only few reports were published in the medical literature.
  • Primary pulmonary lymphoma associated with AIDS is generally a high-grade B-cell non-Hodgkin lymphoma and Epstein-Barr virus is strongly associated with the pathogenesis of these tumors.
  • We report a patient with AIDS and primary pulmonary lymphoma which clinical presentation was a total atelectasis of the left lung.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Atelectasis / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16138208.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


63. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Møller H, Bower M: Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol; 2009 Feb 20;27(6):884-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
  • PURPOSE: The effect of highly active antiretroviral therapy (HAART) on the incidence of non-AIDS-defining cancers (NADCs) is unclear.
  • METHODS: We have investigated the occurrence of NADCs in a prospective cohort of 11,112 HIV-positive individuals, with 71,687 patient-years of follow-up.
  • We investigated the effect of calendar period, HIV parameters, and immunologic and treatment-related factors on the incidence of these cancers using univariate and multivariate analyses.
  • Multivariate analysis showed that use of HAART (hazard ratio [HR] = 1.64; 95% CI, 1.13 to 2.39) and a nadir CD4 count less than 200/microL (HR = 1.67; 95% CI, 1.10 to 2.54) were associated with an increased risk.
  • Only the non-nucleoside reverse transcriptase inhibitors (NNRTIs) were associated with a significantly increased risk of NADCs (HR = 1.45; 95% CI, 1.01 to 2.08).
  • Much of this association was attributable to an increased risk of Hodgkin's lymphoma with NNRTIs (HR = 2.20; 95% CI, 1.03 to 4.69).
  • A number of factors are associated with this increased risk, including HAART use.
  • There may be an association between the use of NNRTIs and the development of Hodgkin's lymphoma.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active / adverse effects. HIV Infections / drug therapy. Neoplasms / epidemiology


64. Spina M, Tirelli U: Rituximab for HIV-associated lymphoma: weighing the benefits and risks. Curr Opin Oncol; 2005 Sep;17(5):462-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab for HIV-associated lymphoma: weighing the benefits and risks.
  • PURPOSE OF REVIEW: This review discusses the potential benefits and risks of using the anti-CD20 monoclonal antibody rituximab for the treatment of HIV-associated B-cell non-Hodgkin's lymphoma.
  • RECENT FINDINGS: Studies have consistently demonstrated that rituximab improves response and survival when combined with standard chemotherapy compared with chemotherapy alone in immunocompetent patients with intermediate-grade non-Hodgkin's lymphoma.
  • Several recently reported phase II and III trials have evaluated the use of rituximab plus chemotherapy for HIV-associated B-cell non-Hodgkin's lymphoma.
  • Phase II trials combining rituximab with either standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy or infusional chemotherapy have reported encouraging results, suggesting a similar benefit in HIV-positive individuals.
  • A phase III trial comparing CHOP with CHOP-plus rituximab (R-CHOP) demonstrated a lower risk from progression of the lymphoma, but a higher risk of early and late infectious-related death in patients with a low CD4 count (< 50/microL).
  • SUMMARY: Rituximab should be used cautiously in patients with advanced HIV infection who have a CD4 count of less than 50/microL, as it seems to increase the risk of developing fatal infectious complications.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093796.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 19
  •  go-up   go-down


65. Kiertiburanakul S, Likhitpongwit S, Ratanasiri S, Sungkanuparph S: Malignancies in HIV-infected Thai patients. HIV Med; 2007 Jul;8(5):322-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies in HIV-infected Thai patients.
  • Of 1416 HIV-infected patients seen at Ramathibodi Hospital over a 5-year period (1999-2003), 42 were diagnosed with malignancies, giving a prevalence of 3%.
  • AIDS-related malignancies were found in 26 patients (62%).
  • The most common AIDS-related malignancies were non-Hodgkin's lymphoma (NHL) (33%), cervical cancer (21%) and Kaposi's sarcoma (KS) (5%).
  • Breast cancer was the most common non-AIDS-related malignancy (10%).
  • [MeSH-major] HIV. HIV Infections / complications. Neoplasms / virology


66. Tanaka PY, Pracchia LF, Calore EE: Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil. Int J Hematol; 2006 Nov;84(4):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil.
  • The relative risk of non-Hodgkin's lymphoma (NHL) among patients infected with human immunodeficiency virus (HIV) is elevated compared with the general population.
  • We describe a retrospective study of 78 HIV-infected patients with NHL treated between 1999 and 2006 at the Infectology Institute, a reference center for HIV treatment in São Paulo, Brazil.
  • A univariate analysis showed a significant CR rate in patients with respect to the following factors: no acquired immunodeficiency syndrome (AIDS) diagnosis prior to the lymphoma, disease stage of I to II, and an International Prognostic Index (IPI) of low or low-intermediate risk.
  • A multivariate analysis indicated that only a previous AIDS diagnosis and the IPI were significantly related to the CR rate.
  • A median disease-free survival (DFS) time for the patients who achieved a CR was not reached, with a mean survival time of 73 months and a 3-year DFS rate of 77.5%.
  • Our results provide additional information regarding HIV-related lymphoma in Brazil.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Brazil. Cyclophosphamide. Disease-Free Survival. Doxorubicin. Female. Humans. Male. Middle Aged. Prednisolone. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1165-73 [8118021.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Blood. 2006 Apr 1;107(7):3014-5 [16554492.001]
  • [Cites] Blood. 1992 Jul 1;80(1):8-20 [1319239.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):79-87 [10561022.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Lancet. 2000 Jul 22;356(9226):291-6 [11071184.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):442-53 [10950371.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):402-3 [2992336.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Oncology (Williston Park). 2001 Apr;15(4):439-48; discussion 448-9 [11346932.001]
  • (PMID = 17118760.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


67. Diamond C, Taylor TH, Im T, Miradi M, Wallace M, Anton-Culver H: Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma. Curr HIV Res; 2006 Jul;4(3):375-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma.
  • We sought to determine how the use of HAART influenced survival among patients with acquired immunodeficiency syndrome (AIDS) and primary central nervous system (CNS) non-Hodgkin's lymphoma (NHL).
  • We used the population-based San Diego and Orange County cancer registry to identify 94 patients with both AIDS and CNS NHL diagnosed 1994-1999, of whom 31 were diagnosed 1996-1999.
  • Median survival was eight months for those who received HAART at the time of lymphoma diagnosis or after, versus one month for untreated patients.
  • HAART, radiation therapy, and better performance status were associated with improved survival.
  • We conclude that HAART prolongs survival in AIDS-related CNS NHL.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Central Nervous System Neoplasms / mortality. Lymphoma, AIDS-Related / mortality


68. Svec MA, Ward MH, Dosemeci M, Checkoway H, De Roos AJ: Risk of lymphatic or haematopoietic cancer mortality with occupational exposure to animals or the public. Occup Environ Med; 2005 Oct;62(10):726-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To conduct a population based, case-control study of death certificate data from 1984 to 1998 in 24 US states in order to evaluate the risk of mortality from LH neoplasms associated with occupational exposure to animals or the public.
  • METHODS: Cases were selected as those with an underlying cause of death of non-Hodgkin's lymphoma (NHL, n = 72,589), Hodgkin's disease (HD, n = 5479), multiple myeloma (n = 35,857), or leukaemia (n = 68,598); 912 615 controls were randomly selected from all remaining deaths, frequency matched on age, sex, race, and geographic region.
  • RESULTS: Occupational exposure to animals was associated with modest increased risks of mortality from all four LH cancers; these associations varied by region.
  • Occupational exposure to the public was associated with only negligible increased risk with LH cancer outcomes.
  • Occupations involving animal exposure were predominantly agricultural, and the risks associated with employment in the livestock industry exceeded the corresponding risks associated with the crop industry for all outcomes except HD.
  • CONCLUSIONS: Increased risks of NHL, HD, multiple myeloma, and leukaemia were associated with occupations that involved animal exposure.
  • Regional differences in risk imply that the risks may be associated with exposure to specific livestock or farming practices.
  • However, these associations may be confounded by other farming related exposures, such as pesticides.
  • [MeSH-minor] Animals. Case-Control Studies. Death Certificates. Disease Transmission, Infectious. Humans. Leukemia / etiology. Leukemia / microbiology. Lymphoma / etiology. Lymphoma / microbiology. Registries. Retrospective Studies. Risk Factors. United States / epidemiology. Zoonoses

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Infectious Diseases.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Work Environ Health. 1999 Feb;25(1):5-17 [10204665.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):60-9 [10361588.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):155-8 [10361601.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):159-65 [10361602.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):186-92 [10361605.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Cancer Invest. 2000;18(4):366-80 [10808373.001]
  • [Cites] Cancer Invest. 2000;18(5):467-79 [10834031.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):78-87 [11138825.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):371-6 [11317081.001]
  • [Cites] Am J Ind Med. 2001 Jul;40(1):3-14 [11439392.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):135-9 [11458277.001]
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):509-17 [11519759.001]
  • [Cites] Cancer Causes Control. 2001 Sep;12(7):635-43 [11552711.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):657-9 [11956646.001]
  • [Cites] J Occup Environ Med. 2002 May;44(5):469-74 [12024692.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):78-9 [12110734.001]
  • [Cites] Cancer Causes Control. 2002 Aug;13(6):563-71 [12195646.001]
  • [Cites] Am J Ind Med. 2002 Aug;Suppl 2:54-61 [12210683.001]
  • [Cites] Am J Ind Med. 2002 Nov;42(5):410-20 [12382254.001]
  • [Cites] J Occup Environ Med. 2003 Aug;45(8):857-68 [12915787.001]
  • [Cites] Eur J Cancer Prev. 2003 Dec;12(6):517-26 [14639130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):425-30 [15006919.001]
  • [Cites] Epidemiology. 2004 May;15(3):352-6 [15097020.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):713-24 [15158093.001]
  • [Cites] Scand J Work Environ Health. 2004 Jun;30(3):215-22 [15250650.001]
  • [Cites] Public Health Rep. 1970 Sep;85(9):815-27 [4989476.001]
  • [Cites] Am J Epidemiol. 1971 Oct;94(4):507-10 [5165015.001]
  • [Cites] J Natl Cancer Inst. 1974 Jul;53(1):45-9 [4858064.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1489-91 [857036.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Ann Intern Med. 1978 Oct;89(4):550-6 [697236.001]
  • [Cites] Am J Epidemiol. 1980 Jul;112(1):80-92 [6930819.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] Am J Epidemiol. 1982 May;115(5):720-8 [7081203.001]
  • [Cites] Int J Epidemiol. 1982 Dec;11(4):391-7 [7152791.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Oct 8;287(6398):1017-9 [6412930.001]
  • [Cites] J Natl Cancer Inst. 1984 Feb;72(2):251-5 [6582313.001]
  • [Cites] Am J Ind Med. 1984;6(2):97-102 [6465143.001]
  • [Cites] Am J Ind Med. 1984;6(3):185-205 [6475965.001]
  • [Cites] Am J Epidemiol. 1985 May;121(5):675-83 [4014159.001]
  • [Cites] Br J Ind Med. 1986 Feb;43(2):75-83 [3753879.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):402-9 [3740040.001]
  • [Cites] Br J Cancer. 1986 Sep;54(3):493-500 [3756085.001]
  • [Cites] Int J Cancer. 1987 Feb 15;39(2):155-61 [3804490.001]
  • [Cites] Am J Vet Res. 1987 Feb;48(2):235-8 [3030166.001]
  • [Cites] Am J Epidemiol. 1987 Dec;126(6):1051-62 [3687917.001]
  • [Cites] Br J Ind Med. 1988 Jan;45(1):25-8 [3342184.001]
  • [Cites] Am J Ind Med. 1988;13(3):317-30 [3354583.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2919-22 [2834051.001]
  • [Cites] J Occup Med. 1989 Mar;31(3):270-2 [2918412.001]
  • [Cites] Int J Cancer. 1989 Apr 15;43(4):554-9 [2703267.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3605-9 [2340508.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]
  • [Cites] Am J Epidemiol. 1991 Jul 1;134(1):22-8 [1853857.001]
  • [Cites] Br J Ind Med. 1992 Feb;49(2):95-103 [1536825.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2447-55 [1568215.001]
  • [Cites] Br J Ind Med. 1993 Jan;50(1):79-84 [8431395.001]
  • [Cites] Am J Ind Med. 1993 May;23(5):729-42 [8506851.001]
  • [Cites] Soc Sci Med. 1993 Sep;37(6):771-7 [8211293.001]
  • [Cites] Am J Epidemiol. 1994 Mar 15;139(6):609-19 [8172172.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] J Occup Med. 1994 Nov;36(11):1210-21 [7861265.001]
  • [Cites] Occup Environ Med. 1995 Jun;52(6):374-9 [7627313.001]
  • [Cites] Am J Ind Med. 1995 Jun;27(6):817-35 [7645576.001]
  • [Cites] Br J Haematol. 1995 Sep;91(1):154-61 [7577624.001]
  • [Cites] Lancet. 1996 Mar 2;347(9001):624-5 [8596360.001]
  • [Cites] Blood. 1996 May 15;87(10):4296-301 [8639788.001]
  • [Cites] Scand J Soc Med. 1996 Jun;24(2):114-20 [8816000.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):754-8 [8980179.001]
  • [Cites] Vet Clin North Am Food Anim Pract. 1997 Mar;13(1):177-90 [9071753.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):551-8 [9270958.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Am J Public Health. 1997 Sep;87(9):1539-43 [9314812.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Int J Epidemiol. 1997 Dec;26(6):1142-50 [9447392.001]
  • [Cites] Am J Epidemiol. 1998 Apr 15;147(8):727-38 [9554414.001]
  • [Cites] Occup Environ Med. 1998 Aug;55(8):522-7 [9849538.001]
  • (PMID = 16169919.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1740863
  •  go-up   go-down


69. Foschi D, Rizzi A, Corsi F, Trabucchi E, Corbellino M: Chylous ascites secondary to B-cell non Hodgkin's lymphoma in a patient with the acquired immune deficiency syndrome (AIDS). Dig Liver Dis; 2008 Jun;40(6):481-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chylous ascites secondary to B-cell non Hodgkin's lymphoma in a patient with the acquired immune deficiency syndrome (AIDS).
  • In the present article we describe a patient with AIDS and chylous ascites secondary to B-cell non Hodgkin's lymphoma.
  • A 43 years old homosexual HIV-positive man.
  • All blood tests and analysis of the peritoneal fluid with polymerase chain reaction for DNA sequence of broad-range bacterial Post Voiding Residual volume, Mycobacterium tuberculosis, Kaposi Sarcoma associated Herpes virus and Epstein Barr Virus were negative.
  • The final pathology report was of diffuse, CD20-positive, CD3-negative, Epstein Barr Virus-negative, large B-Cell non Hodgkin's lymphoma.
  • Five months after the initial diagnosis of lymphoma, the patient relapsed and was treated with high-dose BEAM (carmustine, etoposide, cytosine, arabinoside, melphalan) chemotherapy followed by CD34 stem-cell transplantations salvage therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Chylous Ascites / etiology. Lymphoma, AIDS-Related / complications. Lymphoma, B-Cell / complications
  • [MeSH-minor] Adult. HIV-1. Humans. Male. Paracentesis. Tomography, X-Ray Computed


70. Villafañe MF, Trione N, Corti M, Mendez N, Gancedo E, Zamora N, Levin M: Primary liver AIDS-related lympoma. Rev Inst Med Trop Sao Paulo; 2006 Jul-Aug;48(4):229-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver AIDS-related lympoma.
  • Non-Hodgkin's lymphomas (NHL) are the second most frequent malignancies in AIDS patients.
  • The majority of NHL associated with AIDS involves extranodal sites, especially the digestive tract and the central nervous system.
  • Primary liver lymphoma (PLL) is an uncommon neoplasm among these patients.
  • Ultrasonography and computed tomography scans may be helpful in the diagnosis of focal hepatic lymphoma.
  • Image-guided fine-needle biopsy with histopathology of the liver lesions is the gold standard for the diagnosis of hepatic lymphoma.
  • We report a case of PLL as the initial manifestation of AIDS in a patient without any previous infection by hepatitis C or B virus, presented as multiple and large hepatic masses.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119682.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


71. Makinson A, Martelli N, Peyrière H, Turriere C, Le Moing V, Reynes J: Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol; 2007 Apr;78(4):358-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease.
  • A HIV infected patient was treated for stage IVB Hodgkin's lymphoma by ABVD (doxorubicine, bleomycine, vinblastine, dacarbazine) chemotherapy and lopinavir-ritonavir based antiretroviral therapy inducing profound life-threatening neutropenia.
  • [MeSH-major] Anti-HIV Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Neutropenia / chemically induced. Vinblastine / adverse effects

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378895.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


72. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • One of the major clinical characteristics of AIDS-associated NHL is the high frequency of extra-nodal involvement, including the gastrointestinal tract, at initial presentation.
  • METHODS: From January 1997 to December 2004, 8 cases of NHL of the digestive tract and anexal glands (liver and parotid gland) were observed at the HIV/AIDS division of the Infectious Diseases FJ Muñiz Hospital from Buenos Aires, Argentina.
  • No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • CONCLUSION: NHL of the gastrointestinal tract is a severe complication of advanced HIV/AIDS disease.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis


73. Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF: Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med; 2005 Jan;6(1):21-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
  • BACKGROUND: Neurological disorders are common in HIV-infected patients.
  • Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.
  • OBJECTIVES: To investigate the clinical utility of flow cytometry immunophenotyping (FCI) in diagnosing or discarding leptomeningeal involvement in HIV-infected patients and to compare its sensitivity with that of conventional cytological methods.
  • METHODS: Fifty-six cerebrospinal fluid (CSF) samples from 29 HIV-infected patients were independently evaluated by flow cytometry and cytology.
  • RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.
  • This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670248.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Reed M, Cosgrove JM, Cindrich R, Parithivel VS, Gad Y, Bangalore M, Uzor R, Kalim J, Segura R, Albu E: Ten years later: a single hospital experience with malignancy in HIV/AIDS. J Surg Oncol; 2010 Sep 1;102(3):282-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten years later: a single hospital experience with malignancy in HIV/AIDS.
  • BACKGROUND AND OBJECTIVE: We present our experience in the era of HAART with 5,112 patients having HIV infection or AIDS, treated between 2002 and 2006 in our hospital, 182 of whom had malignancies (3.56%).
  • A decrease in AIDS-defining cancers (ADC), from 63.6% to 37.3% and a higher incidence of non-AIDS-defining cancers (NADC), 62.7 as opposed to 37.9% was found.
  • No decrease in the incidence of non-Hodgkin's B cell lymphoma (NHL) was noted.
  • CONCLUSIONS: HIV/AIDS patients on HAART are older, have lower rates of AIDS related Kaposi's sarcoma and a higher incidence of NADCs than did patients in the early HAART era.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. HIV Infections / complications. Neoplasms / epidemiology


75. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, Ness A, Reynolds S, Johnson JL, Subbiah V, Bako J, Wabinga H, Abdallah FK, Meyerson HJ, Whalen CC, Lederman MM, Black J, Ayers LW, Katongole-Mbidde E, Remick SC: Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol; 2009 Jul 20;27(21):3480-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
  • PURPOSE Africa is burdened by the AIDS epidemic and attendant increase in HIV/AIDS-related malignancies.
  • Dose-modified oral chemotherapy for AIDS-related non-Hodgkin's lymphoma is one such approach.
  • PATIENTS AND METHODS The oral regimen consisted of lomustine 50 mg/m(2) on day 1 (cycle 1 only), etoposide 100 mg/m(2) on days 1 to 3, and cyclophosphamide/procarbazine 50 mg/m(2) each on days 22 to 26 at 6-week intervals (one cycle) for two total cycles in HIV-infected patients with biopsy-proven non-Hodgkin's lymphoma.
  • The majority of patients were female (59%) and had a poor performance status (63%); 69% of patients had advanced-stage disease; and 18 patients (37%) had access to antiretroviral therapy.
  • The regimen was well tolerated, had modest effects (decline) on CD4(+) lymphocyte counts (P = .077), and had negligible effects on HIV-1 viral replication.
  • Four febrile neutropenia episodes and three treatment-related deaths (6% mortality rate) occurred.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV-1 / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Africa South of the Sahara. Antiretroviral Therapy, Highly Active / trends. CD4 Lymphocyte Count. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. HIV Infections / complications. HIV Infections / drug therapy. Hematopoietic Stem Cell Transplantation. Humans. Kenya. Lomustine / therapeutic use. Male. Middle Aged. Procarbazine / therapeutic use. Treatment Outcome. Uganda. Virus Replication / drug effects. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):532-40 [14595710.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] Am J Med. 1986 Jan;80(1):119-22 [3942143.001]
  • [Cites] Ann Intern Med. 1989 Jun 1;110(11):937-40 [2719427.001]
  • [Cites] Rev Infect Dis. 1989 Nov-Dec;11(6):954-63 [2690289.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3(4):430-7 [2313564.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] Blood. 1993 May 15;81(10):2810-5 [8490187.001]
  • [Cites] Drugs. 1999;58 Suppl 3:99-107 [10711848.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Ann N Y Acad Sci. 2000 Nov;918:362-6 [11131726.001]
  • [Cites] Am J Hematol. 2001 Mar;66(3):178-88 [11279624.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] Biometrics. 1999 Jun;55(2):625-9 [11318225.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] J Am Coll Nutr. 2001 Dec;20(6):609-15 [11771676.001]
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):718-32 [12011222.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1691-702 [8355036.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leuk Lymphoma. 1994 Jul;14(3-4):263-71 [7950915.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):3026-35 [8918501.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] AIDS. 1998;12 Suppl 1:S3-14 [9677185.001]
  • [Cites] Haematologica. 1998 Jun;83(6):508-13 [9676023.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3601-6 [9817281.001]
  • [Cites] Pediatr Blood Cancer. 2005 Mar;44(3):245-50 [15547922.001]
  • [Cites] Cancer Detect Prev. 2005;29(2):133-45 [15829373.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S155-60 [16619692.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):479-86 [16894296.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1141-53 [16971720.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):319 [18380064.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):398-403 [18385682.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19470940.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / TW00011; United States / NCI NIH HHS / CA / R01 CA083528; United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA83528; United States / NCI NIH HHS / CA / U01 CA070081; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA066531; United States / NCI NIH HHS / CA / CA43703; United States / FIC NIH HHS / TW / D43 TW000011; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / U01 CA066531; United States / NIAID NIH HHS / AI / P30 AI036219
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2717754
  •  go-up   go-down


76. Steingass SK: Hematopoietic cell transplantation in non-Hodgkin's lymphoma. Semin Oncol Nurs; 2006 May;22(2):107-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic cell transplantation in non-Hodgkin's lymphoma.
  • OBJECTIVE: To explore the role and outcomes using hematopoietic cell transplantation (HCT) as a treatment option with aggressive, follicular, mantle, T-cell, and HIV related non-Hodgkin's lymphoma (NHL).
  • CONCLUSION: High-dose chemotherapy and/or radiation therapy followed by HCT has been used to overcome resistance to standard-dose therapy and has been explored over the past 40 years and has shown long-term survival of approximately 10% to 50% in patients with relapsed or refractory lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related / nursing. Lymphoma, AIDS-Related / therapy. Lymphoma, Follicular / nursing. Lymphoma, Follicular / therapy. Lymphoma, Mantle-Cell / nursing. Lymphoma, Mantle-Cell / therapy. Lymphoma, T-Cell / nursing. Lymphoma, T-Cell / therapy. Transplantation Conditioning / adverse effects. Transplantation Conditioning / nursing

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720233.001).
  • [ISSN] 0749-2081
  • [Journal-full-title] Seminars in oncology nursing
  • [ISO-abbreviation] Semin Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


77. Jablonowski H: [Diagnostics of the HIV infection]. MMW Fortschr Med; 2005 Apr 25;147 Spec No 1:5-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostics of the HIV infection].
  • [Transliterated title] Die akute HIV-Infektion wird häufig übersehen. Dran denken, und bei Verdacht nicht mit dem H1V-test zögern!
  • Diagnostics of the HIV Infection The clinical picture of an acute HIV infection resembles that of mononucleosis with lymphadenopathy, fatigue and fever.
  • Ulcerations in atypical locations of the gastrointestinal tract could also indicate an HIV infection.
  • For cases of clear lymphopenia, an HIV infection should be definitely considered.
  • Above all, the presence of non-Hodgkin's lymphoma is characteristic of the complete clinical picture of AIDS.
  • An appropriate diagnostic test (antibody test or detection of HIV) is urgently indicated in situations that carry a high risk for HIV transmission.
  • This applies, above all, to patients whose partner is HIV positive, to patients who frequently change sex partners, to prostitutes and to intravenous drug users.
  • [MeSH-major] AIDS Serodiagnosis. HIV Infections / diagnosis
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. Diagnosis, Differential. Early Diagnosis. Germany. HIV Seroprevalence. Humans

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16385861.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Metta H, Corti M, Maranzana A, Schtirbu R, Narbaitz M, De Dios Soler M: Unusual case of plasmablastic non-Hodgkin's lymphoma located in the liver. First case reported in an AIDS patient. Ann Hepatol; 2009 Jul-Sep;8(3):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual case of plasmablastic non-Hodgkin's lymphoma located in the liver. First case reported in an AIDS patient.
  • Plasmablastic lymphoma is a rare and a relatively new entity that was first described in the jaws and the oral cavity of HIV-AIDS patients.
  • We report a case of plasmablastic lymphoma involving the liver in an AIDS patient.
  • Plasmablastic lymphoma is considered a diffuse large B-cell lymphoma with a unique phenotype and predilection for the oral cavity.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Non-Hodgkin / diagnosis


79. Khan F, Bauer F, Gazi G, Bilgrami S: Regression of large B-cell non-Hodgkin's lymphoma of stomach with HAART: case report and review. Leuk Lymphoma; 2006 Apr;47(4):750-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of large B-cell non-Hodgkin's lymphoma of stomach with HAART: case report and review.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy


80. Lan K, Verma SC, Murakami M, Bajaj B, Robertson ES: Epstein-Barr Virus (EBV): infection, propagation, quantitation, and storage. Curr Protoc Microbiol; 2007 Aug;Chapter 14:Unit 14E.2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) was first reported as the etiological agent of Burkitt's lymphoma in 1964.
  • Since then, EBV has also been associated with nasopharyngeal carcinoma, which is highly prevalent in Southeast Asia, as well as infectious mononucleosis, complications of AIDS, and transplant-related B cell lymphomas.
  • This virus has further been linked with T cell lymphomas and Hodgkin's disease, establishing the concept of a wide spectrum of EBV-associated malignant disorders.
  • So far, there are a number of EBV-infected cell lines established that can be induced for production of infectious viral progeny and that facilitate the study of the mechanism of EBV-related infection, transformation, and oncogenesis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18770612.001).
  • [ISSN] 1934-8533
  • [Journal-full-title] Current protocols in microbiology
  • [ISO-abbreviation] Curr Protoc Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media
  •  go-up   go-down


81. Martí-Carvajal AJ, Cardona AF, Rodríguez ML: Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults. Cochrane Database Syst Rev; 2007;(2):CD006149
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults.
  • BACKGROUND: Hodgkin's disease (HD) is the most common non-AIDS-defining malignancy in HIV-infected patients.
  • Its unusually aggressive tumour behaviour includes a higher frequency of unfavourable histologic subtypes, high-stage and extranodal involvement by the time of presentation (anal canal, stomach), and poor therapeutic outcome, in comparison with HD outside the HIV setting.
  • Thus, there is a need to identify the efficacy and safety of different interventions for AIDS-associated HD on overall survival and disease-free survival in treatment-naive adults with AIDS.
  • OBJECTIVES: To assess the effects of different interventions for treating AIDS-associated Hodgkin's disease including chemotherapy, bone marrow transplantation (BMT), and gene therapy on overall survival and disease-free survival in treatment-naive adults with AIDS.
  • SEARCH STRATEGY: We searched The Cochrane HIV/AIDS Group Trials Register (September 2006), which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings.
  • MAIN RESULTS: We were unable to find any randomised controlled trials of interventions for treating AIDS-associated HD in treatment-naive adults with AIDS.
  • AUTHORS' CONCLUSIONS: Randomised controlled trials are needed to establish the efficacy and safety of interventions for treating AIDS-associated HD in treatment-naive adults with AIDS.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy